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INTRODUCTION
The Oral route of administration still continues to be the most preferred route
due to its manifold advantages including ease of ingestion, pain avoidance,
versatility and most importantly patient compliance. Therefore, oral solid dosage
forms are popular because of ease of administration, accurate dosage, self
medication, pain avoidance and most importantly patient compliance.
Among the pharmaceutical dosage forms, the conventional tablets seem to be most
popular, because of its ease of transportability and comparatively lower
manufacturing cost.
There are several factors other than physicochemical properties of the drug
that may influence the dissolution rate and hence, bioavailability of the drugs forms
the solid dosage forms. It has shown that, the dissolution rate of pure drugs can be
altered significantly by the proper selection of formulation components as well as
processing methods.
Of the solid oral dosage forms tablets and capsules are more commonly
employed. The tablets have advantages than capsules in that they are tamper
resistant and any adulterant of the tablet after its manufacture is almost certain to be
observed. The adulteration can be easily found if it is done in either liquid form or
solid form since deformation takes place if it is done in liquid form and powders
cannot be added to the tablet if once they are formed. The major disadvantage of
capsules over tablets is their higher cost. The capsules either hard capsule or soft
capsule are susceptible to breakage if they are not stored properly.
Topical route is recently developed and is employed for only few drugs like
nitroglycerine, scopolamine for systemic effect. Topical route has limitations in its
ability to allow effective drug absorption for systemic drug action. Nevertheless it is
possible that at least 90 % of all drugs used to produce systemic effect are
administered by oral route.1
During the past four decades, the pharmaceutical industry has invested vast
amounts of time and money in the study of tablet compaction. The expenditure is
quite reasonable when one considers how valuable tablets, as a dosage form, are to
the industry. Because oral dosage forms can be self-administered by the patient, they
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are obviously more profitable to manufacture than parenteral dosage forms that must
be administered, in most cases, by trained personnel.2
Tablets are popular for several reasons: 3
 The oral route represents a convenient and safe way of drug administration.
 The preparation procedure enables accurate dosing of the drug
 Tablets are convenient to handle and can be prepared in a versatile way
with respect to their use and to the delivery of the drug.
 Tablets can be mass produced with robust and quality-controlled production
Procedures giving an elegant preparation of consistent quality and, in relative
terms, low price.
Tablets are the manufacturer’s dosage form of choice because of their
relatively low cost of manufacture, package and shipment, increased stability and
virtual tamper resistance.2
The disadvantage of tablet includes dysphasia or difficulty in swallowing is
seen to affect nearly 35 % of population. This disorder is also associated with
number of medical conditions including stroke, Parkinson’s disease, AIDS, head and
neck radiation therapy and other neurological disorders including cerebral palsy.
Many elder persons will have difficulty in taking conventional dosage forms
because of hand tremors and dysphasia. Swallowing problems are also common in
young individuals because of their under developed muscular and nervous tissue.
Others who may experience problems in swallowing are the mentally ill,
developmentally disabled uncooperative patients and reduced liquid intake plan and
nausea. In some cases such as motion sickness, sudden episode of allergic attack or
coughing and unavailability of water swallowing tablets may become difficult.4
To fulfill the above needs pharmaceutical technologists have developed a
novel type of dosage form for oral administration, fast dissolving tablets. Fast
dissolving tablets are also called rapimelts, quick disintegrating tablets, oral
disintegrating tablets etc.
Fast dissolving tablets are defined as the tablets, which are meant to
disintegrate immediately upon contact with the saliva leading to faster release of the
drugs in the oral cavity and disintegrate rapidly within 15 seconds to 3 minutes. The
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faster the drug goes into solution, faster is the absorption and onset of clinical effect.
For the drug attaining the therapeutic level by the gastric wall and elicit therapeutic
effect, both rate and extent of absorption is important. The conventional tablet shows
the delay in absorption and fast dissolving tablets disintegrate and dissolve rapidly
and absorption takes place quickly, thus bioavailability increases.5
Some factors like GI disturbances and blood supply to GI differs with age as
the elderly are considered as separate unique medicare population.5
Ideal characteristics of fast dissolving tablets4, 6
 They should not require water or other liquid at the time of administration.
 Should easily disintegrate and dissolve.
 Mask or overcome unacceptable taste of drug.
 They should have high drug loading.
 They should have pleasant feel in the mouth.
 They should have negligible or no residue in oral cavity after administration
 They should have low sensitivity against environmental conditions like moisture,
temperature etc.
 Ease of administration for patients who are mentally ill, disabled and
uncooperative.
 Should be portable without fragility concern.
 They should be manufactured using conventional tablet processing and packing
equipment at low cost.
Advantages of fast dissolving tablets6, 7
 Ease of administration to patients who refuses to swallow a tablet such as
pediatrics, geriatric patients and psychiatric patients.
 No need or little water is required to swallow the dosage form which is highly
convenient feature for patients who are traveling and do not have access to
water.
 Free of risk of suffocation due to physical obstruction when swallowed, thus
offering improved safety.
Chapter 1 Introduction
Dept of Pharmaceutics 4 J.K.K.Nattraja College of Pharmacy
 Rapid disintegration and absorption of drug, which will produce quick onset of
action.
 Quick absorption from the gastro intestinal tract improves bioavailability and
reduces unwanted effects caused by the drugs and also improves patient
compliance.
 Drug and dosage form stability.
 New business opportunities like product differentiation, line extension and life
cycle management. Exclusivity of product promotion.
 Although chewable tablets have been on the market for some time, they are not
the same as the new fast dissolving tablets. Patients for whom chewing is
difficult or painful can use these new tablets easily. Fast dissolving tablets can be
used easily in children who have lost their primary teeth, but do not have full use
of their permanent teeth.
Disadvantages of FDT8
 Most fast dissolving tablets lack the mechanical strength common to traditional
tablets. Many products are very lightweight and fragile requiring them to be
individually packaged. Patients should be advised not to push these tablets
through the foil film, but instead, peel the film back to release the fast-dissolving
tablet.
 Due to the formulation of fast dissolving tablets which are also more susceptible
to degradation via temperature and humidity, some of the newest fast dissolving
tablet formulations are dispensed in a conventional stock bottle. Pharmacists are
advised to take care when dispensing such formulations to ensure they are not
exposed to high levels of moisture or humidity. Excess handling of tablets can
introduce enough moisture to initiate dissolution of the tablet matrix.
Developmental challenges in fast dissolving drug delivery
The fast dissolving tablet formulation is defined by the food and drug
administration (FDA) as, “A solid dosage form containing medicinal substances
which disintegrates rapidly, usually within matter of seconds, when placed upon
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the tongue.”7 It is difficult for many patient to swallow tablets and hard gelatin
capsule hence they do not comply with prescription, which results in high
incidence of non compliance and ineffective therapy. Such problem can be
resolved by mean of fast dissolving tablet. These FDT are designed to dissolve or
disintegrates rapidly in saliva generally within <60 second.
1. Taste of the active ingredient9:
Some drugs have relatively no taste, and simply adding a suitable flavor can
hide any slight unpleasant sensation. However, most drugs do require taste masking
if they are to be incorporated into fast dissolving formulations. Numerous methods
exist to achieve this, including simple wet granulation or roller compression with
other excipients to minimize the presented surface area of the drug. Spray drying can
also be employed to shroud the drug.
If further taste masking is needed, the resultant particle can be sealed with a
suitable coating material (like hydroxy propyl methyl cellulose, ethyl cellulose,
methacrylate and polyvinylpyrollidone). The choice of coating material will
determine the mechanism of taste masking. In addition, the quantity of coat applied,
how it is applied, and where other excipients are included in the coating will all
affect the quality of taste masking.
Cyclodextrins (cyclic linked oligosaccharides) have been shown to prove
some measure of taste masking by trapping the drug within the cyclic structure long
enough to render initial dissolution. Other taste masking methods are namely coating
methods including electrochemical, hot melt and super critical fluids. Encapsulation
using coacervation has also been employed to encapsulate certain drugs.
2. Dose:
Molecules requiring high doses present three challenges to development of
fast dissolving dosage forms: 1) Taste masking of active substance, 2) mouth-feel or
grittiness and 3) tablet size. These challenges are not unrelated because most drugs
will require taste masking depending on the degree of bitterness relative to the dose
of the drug, which will in turn affect the final tablet size. As mentioned previously,
drug may require coating, which will result in an increase in the particle size. The
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extent to which this increase will affect the mouth feel and tablet size will depend on
the dose of the drug and the amount of coating material required masking its taste.
3. Hygroscopy10:
Several fast dissolving dosage forms are hygroscopic and cannot maintain
physical integrity under normal conditions of temperature and humidity. Hence they
need protection from humidity that calls for specialized product package.
4. Friability6:
In order to allow fast dissolving tablets to disintegrating rapidly in the mouth, they
are made of either very porous or soft moulded matrices or compressed into tablets
with low compression force, which makes the tablet friable and/or brittle which are
difficult to handle, often require specialized peel-off blister packing.
Techniques used in FDT6:
The performance of fast dissolving tablets depends on the technology used in
their manufacture. The orally disintegrating property of the tablet is attributable to a
quick ingress of water into the tablet matrix, which creates porous structure and
results in rapid disintegration. Hence, the basic approaches to develop fast
dissolving tablets include maximizing the porous structure of the tablet matrix,
incorporating the appropriate disintegrating agent and using highly water-soluble
excipients in the formulation.
Following technologies have been used by various researchers to prepare fast
dissolving tablets: -
 Freeze-Drying or Lyophilization
 Tablet Molding
 Spray Drying
 Sublimation
 Direct Compression
 Cotton Candy Process
 Mass-Extrusion
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Freeze-Drying or Lyophilization11-14:
Freeze drying is the process in which water is sublimed from the product
after it is frozen. This technique creates an amorphous porous structure that can
dissolve rapidly. Commonly used excipients with their uses and examples employed
in manufacturing of fast dissolving tablets using Freeze-drying are listed on next
page.
A typical procedure involved in the manufacturing of fast dissolving tablets
using this technique is mentioned here. The active drug is dissolved or dispersed in
an aqueous solution of a carrier/polymer. The mixture is dosed by weight and
poured in the wells of the preformed blister packs. The trays holding the blister
packs are passed through liquid nitrogen freezing tunnel to freeze the drug solution
or dispersion. Then the frozen blister packs are placed in refrigerated cabinets to
continue the freeze-drying. After freeze-drying the aluminum foil backing is applied
on a blister-sealing machine. Finally the blisters are packaged and shipped.
EXCIPIENTS USE EXAMPLE
Polymer Strength and rigidity
Gelatin, alginate and
dextrin
Polysaccharides
Crystallinity, hardness
and palatability
Mannitol and sorbitol
Collapse protectants Prevents shrinking Glycerin
Flocculating agents Uniform dispersion Xanthan gum and acacia
Preservatives
Prevent microbial and
fungal growth
Parabens
Permeation enhancer
Transmucosal permeability
Enhancer
Sodium lauryl sulphate
pH adjusters Chemical stability Citric acid and sodium
hydroxide
Flavors and sweeteners Patient compliance ------
Water Porous unit formation -------
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The freeze-drying technique has demonstrated improved absorption and
increase in bioavailability. The Zydis formulations consist of a drug physically
trapped in a water-soluble matrix (saccharine mixture and polymer), which is freeze
dried to produce a product that dissolves rapidly when placed in mouth. The ideal
candidate for Zydis technology should be chemically stable and water insoluble and
particle size preferably less than 50 micron. Water soluble drugs might form eutectic
mixtures and not freeze adequately, so dose is limited to 60 mg and the maximum
drug limit is 400 mg for water insoluble drug as large particle sizes might present
sedimentation problems during manufacture.
The major disadvantages of lyophilization technique are that it is expensive
and time consuming; fragility makes conventional packaging unsuitable for these
products and poor stability under stressed conditions.
Tablet Moulding15,16:
The preparation of fast dissolving tablets using molding technology employs
water-soluble ingredients so that the tablet dissolves completely and rapidly. The
active ingredients in most cases are absorbed through the mucosal lining of the
mouth. Molding process is of two types i.e. solvent method and heat method.
Solvent method involves moistening the powder blend with a hydro alcoholic
solvent followed by compression at low pressures in molded plates to form a wetted
mass (compression molding). The solvent is then removed by air-drying. The tablets
manufactured in this manner are less compact than compressed tablets and possess a
porous structure that hastens dissolution.
The heat molding process involves preparation of a suspension that contains
a drug, agar and sugar (e.g. Mannitol or lactose) and pouring the suspension in the
blister packaging wells, solidifying the agar at the room temperature to form a jelly
and drying at 30˚C under vacuum. The mechanical strength of molded tablets is a
matter of great concern. Binding agents, which increase the mechanical strength of
the tablets, need to be incorporated. Taste masking is an added problem to this
technology.
Chapter 1 Introduction
Dept of Pharmaceutics 9 J.K.K.Nattraja College of Pharmacy
Spray Drying5:
Spray drying is used in pharmaceutical industries to produce highly porous
powders. The processing solvent is evaporated rapidly by spray drying, which
renders the product highly porous and thus can be used in manufacturing fast
dissolving tablets.
In this technique, gelatin can be used as a supporting agent and as a matrix,
mannitol as a bulking agent and sodium starch glycolate or croscarmellose sodium
or crospovidone are used as superdisintegrants.
Tablets manufactured from the spray-dried powder have been reported to
disintegrate in less than 20 seconds in aqueous medium.
Sublimation17, 18, 64:
The key to rapid disintegration of fast dissolving tablets is preparation of a
porous structure in the tablet matrix. To generate such a porous matrix, volatile
ingredients are incorporated in the formulation that is later subjected to a process of
sublimation. Highly volatile ingredients like ammonium bicarbonate, ammonium
carbonate, benzoic acid, camphor, naphthalene, urea, urethane and pthalic anhydride
may be compressed along with other excipients into a tablet. This volatile material is
then removed by sublimation leaving behind a highly porous matrix. Tablets
manufactured by this technique have reported to usually disintegrate in 10-20 sec.
Even solvents like cyclohexane, benzene can be used as pore forming agents.
Vacuum drying technique has been very often used by researchers to sublime
the volatile ingredients and thus maximize the porous structure in the tablet matrix.
It is likely that a porous hydrophilic matrix will easily pick up the disintegrating
medium and break quickly.
Direct Compression:
Direct compression represents the simplest and most cost effective tablet
manufacturing technique. This technique can now be applied to preparation of fast
dissolving tablets because of the availability of improved excipients especially
superdisintegrants and sugar based excipients. Direct compression, using directly
compressible excipients is the most commonly used method of preparing fast
dissolving tablets. Directly compressible excipients are very coarse and granular in
Chapter 1 Introduction
Dept of Pharmaceutics 10 J.K.K.Nattraja College of Pharmacy
nature and give a coarse dispersion in the mouth with decreased mouth feel and
compliance. It is very difficult to prepare fast dissolving tablets with drugs having
very low bulk density, higher dose and poor flow property using this technique.
(a) Superdisintegrants19-23:
In many orally disintegrating tablet technologies based on direct
compression, the addition of superdisintegrants principally affects the rate of
disintegration and hence the dissolution. The presence of other formulation
ingredients such as water-soluble excipients and effervescent agents further hastens
the process of disintegration. This technique contains coated crystals and micro
granules along with the disintegrants. In this technology, two types of granules are
used; a disintegrating agent (e.g. modified cellulose- croscarmellose sodium), which
has a high swelling force, and a swelling agent (e.g. starch), which has a low
swelling force.
Other techniques like effervescent tablets in which disintegration is aided by
evolution of carbon dioxide. Saliva activates the effervescent agent, causing the
tablet to disintegrate. Care should be observed because effervescent excipients and
final product require higher protection against humidity conditions.
(b) Sugar Based Excipients24:
This is another approach to manufacture fast dissolving tablets by direct
compression. The use of sugar based excipients especially bulking agents like
dextrose, fructose, isomalt, lactilol, lactose, maltilol, maltose, mannitol, sorbitol,
starch hydrolysate, polydextrose and xylitol, which display high aqueous solubility
and sweetness, and hence impart taste masking property and a pleasing mouth feel.
These excipients under defined manufacturing conditions gives a highly
porous structure and friable exterior structure which helps in faster disintegration of
fast dissolving tablets, they also provide a satisfactory mouth feel and so suitable for
use in preparation of harder fast dissolving tablets by direct compression at low
pressure.
There was no much attention to the direct compression of pharmaceuticals in
the previous days (late 1950s). Now a day’s great deal of attention has been given to
both product and process development. The availability of new materials, new forms
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of old materials and the invention of new machinery has allowed the production of
tablets by simplified and reliable methods. In early 1960’s, the introduction of spray
dried lactose (1960) and avicel (1964) had changed the tablet manufacturing process
and opened avenues of direct compression tableting.
Previously, the word direct compression was used to identify the
compression of a single crystalline compound (i.e. sodium chloride, potassium
chloride, potassium bromide, etc.) into a compact form without the addition of other
substances. Current usage of the term direct compression is used to define the
process by which tablets are compressed directly from the powder blends of active
ingredient/s and suitable excipients. No pre-treatment of the powder blends by wet
or dry granulation is involved.25
In the flow chart the benefits of the direct compression over other methods is
described in the form of least steps involved.
Step Direct compression Dry granulation Wet granulation
1 Mixed / blending of
active drug and
adjuvants
Mixing/blending of Active
drug and adjuvants
Mixing/blending Active drug
and adjuvants
2 Compression Compression to slugs Preparation if binder solution
3 Size reduction of slugs and
sieving
Massing of binder solution of
step 2 with powder mixture
of step 1.
4 Mixing of granules with
pharmaceutical additives.
Wet screening of damp mass
5 Compression Drying of wet granules
6 Resifiting of dried granules
and blending with
pharmaceutical additives.
7 Compression
Chapter 1 Introduction
Dept of Pharmaceutics 12 J.K.K.Nattraja College of Pharmacy
Excipients used in direct compression:
The advent of direct compression is made possible by the commercial
availability of directly compressible tablet vehicles which possess both fluidity and
compressibility. These include wide range of fillers and disintegrants that are
excessively manufactured to suit the condition of direct compression method.
Diluents:25
The directly compressible adjuvant should be free flowing. Flow ability is
required in case of high-speed rotary tablet machines, in order to ensure
homogenous and rapid flow of powder for uniform die filling. Compressibility is
required for satisfactory tableting, i.e., the mass must remain in the compact form
once the compression force is removed. Few excipients can be compressed directly
without elastic recovery.
Dilution potential can be defined as the amount of an active ingredient that
can be satisfactorily compressed in to tablets with the given directly compressible
excipient. A directly compressible adjuvant should have high dilution potential so
that the final dosage form has a minimum possible weight.
A directly compressible adjuvant should be capable of being reworked
without loss of flow or compressibility. On recompression, the adjuvant should
exhibit satisfactory tableting characteristics.
The adjuvant should remain unchanged chemically and physically. The
directly compressible adjuvant should not exhibit any physical or chemical change
on ageing and should be stable to air, moisture and heat.
A directly compressible adjuvant should have a particle size equivalent to the
active ingredients present in the formulation. The particle size distribution should be
consistent from batch to batch.
It should be colorless and tasteless.
It should be relatively cost effective and available in desired time. It should
accept colorants uniformly.
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Dry granulation technique:
The fast dissolving tablets has been prepared by means of dry granulation
technology, which has the following advantages over other techniques of
preparation:
1. It can be used for all types of drugs including moisture sensitive and heat
sensitive.
2. It can be used for drugs having very low bulk density
3. It can be used for poorly compressible drugs and drugs having poor flow property.
4. The tablets can be packed into regular bottles, blister, strip pack or sachets.
5. The tablets can be stored in bulk in drums to be packaged subsequently. Moreover
conventional tablet packaging feeders can be used for packing purpose. The process
of dry granulation is cost effective as it avoids solvents, and the processes of drying
like freeze drying, spray drying etc.
6. This reduces overall reduction in capital expenditure (conventional processing,
packaging, and storage facilities). These dosage forms may be in the form of tablets,
wafers, granules, or granules packed as such along with other pharmaceutically
acceptable additives in a suitable package which upon contact with water, saliva or
aqueous solution disintegrates within a few seconds.
Cotton Candy Process:
The cotton candy process is also known as the “candy floss” process and
forms the basis of the technologies such as Flash Dose (Fuisz Technology). A fast
dissolving tablets is formed using a candyfloss or shear form matrix; the matrix is
formed from saccharides or polysaccharides processed into amorphous floss by a
simultaneous action of flash melting and centrifugal force. The matrix is then cured
or partially recrystallised to provide a compound with good flow properties and
compressibility. The candyfloss can then be milled and blended with active
ingredients and other excipients and subsequently compressed into fast dissolving
tablets. However the high processing temperature limits the use of this technology to
thermo stable compounds only.
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Mass Extrusion: 26
This technology involves softening the active blend using the solvent
mixture of water-soluble polyethylene glycol and methanol and subsequent
expulsion of softened mass through the extruder or syringe to get a cylinder of the
product into even segments using heated blade to form tablets. The dried cylinder
can also be used to coat granules for bitter drugs and thereby achieve taste masking.
New Orally Disintegrating Dosage Forms
Oral films and wafers
Oral films and wafers are the newer technologies in the manufacturing of orally
disintegrating dosage forms. They are thin elegant films of edible water-soluble
polymers of various sizes and shapes like square, rectangle or disc. The strips may
be flexible or brittle, opaque or transparent. They are designed to provide rapid
disintegration on the tongue without the need for water. They have the advantage of
a large specific surface area for disintegration. One or a combination of the
following processes like hot-melt extrusion; solid dispersion extrusion, rolling and
solvent casting are used to manufacture these films. A major limitation of these
dosage forms is low drug loading capacity and limited taste masking option.
ZYDIS (R.P. Scherer, Inc.)14, 16, 27.
Zydis, the best known of the fast-dissolving/disintegrating tablet
preparations, was the first marketed new technology tablet. The tablet dissolves in
the mouth within seconds after placement on the tongue. A Zydis tablet is produced
by lyophilizing or freeze-drying the drug in a matrix usually consisting of gelatin.
The product is very lightweight and fragile, and must be dispensed in a special
blister pack. Patients should be advised not to push the tablets through the foil film,
but instead peel the film back to release the tablet. The Zydis product is made to
dissolve on the tongue in 2 to 3 seconds. The Zydis formulation is also self-
preserving because the final water concentration in the freeze-dried product is too
low to allow for microbial growth. The Zydis formulation utilizes flavors and
sweeteners to optimize the taste of the dosage form.
In addition, it utilizes microencapsulation with specialized polymers or
complexation with ion exchange resins to mask the bitter tasting drug. The
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combination of lyophilization and taste masking creates a product that is both
pleasing to the eye and also to the senses of taste and touch. A major claim of the
Zydis product is increased bioavailability compared to traditional tablets. Because of
its dispersion and dissolution in saliva while still in the oral cavity, there can be a
substantial amount of pregastric absorption from this formulation. Buccal,
pharyngeal and gastric regions are all areas of absorption of the Zydis formulation.
Any pre-gastric absorption avoids first-pass metabolism and can be an advantage in
drugs that undergo a great deal of hepatic metabolism. However, if the amount of
swallowed drug varies, there is the potential for inconsistent bioavailability. While
the claimed increase in bioavailability is debatable, it is clear that the major
advantage of the Zydis formulation is convenience.
There are some disadvantages to the Zydis technology. The process of
freeze-drying is a relatively expensive manufacturing process. As mentioned earlier,
the Zydis formulation is very lightweight and fragile, and therefore should not be
stored in backpacks or the bottom of purses. Finally, the Zydis formulation has poor
stability at higher temperatures and humidities. It readily absorbs water, and is very
sensitive to degradation at humidities greater than 65%. If there is any pinhole or
minor damage to the package, the patient may find the lyophilized product has
collapsed due to absorption of moisture. As with most other drugs, patients should
be advised to avoid storing the Zydis technology in the medicine cabinet in the
bathroom. Patients should use their Zydis formulation within six months of opening
the laminated foil pouch and immediately after opening its individual blister
packaging.
ORASOLV (Cima Labs, Inc.)4, 6, 7
Orasolv was Cima's first fast-dissolving/disintegrating dosage form. The
Orasolv technology, unlike Zydis, disperses in the saliva with the aid of almost
imperceptible effervescence. The Orasolv technology is best described as a fast-
dissolving tablet; the tablet matrix dissolves in less than one minute, leaving coated
drug powder. The taste masking associated with the Orasolv formulation is two-fold.
The unpleasant flavor of a drug is not merely counteracted by sweeteners or flavors;
both coating the drug powder and effervescence are means of taste masking in
Orasolv. This technology is frequently used to develop over-the-counter
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formulations. The major disadvantage of the Orasolv formulations is its mechanical
strength. The Orasolv tablet has the appearance of a traditional compressed tablet.
However, the Orasolv tablets are only lightly compressed, yielding a weaker and
more brittle tablet in comparison with conventional tablets. For that reason, Cima
developed a special handling and packaging system for Orasolv. An advantage that
goes along with the low degree of compaction of Orasolv is that the particle coating
used for taste masking is not compromised by fracture during processing.
Lyophilization and high degrees of compression, as utilized in Orasolv primary
competitors, may disrupt such a taste masking approach.
DURASOLV (Cima Labs, Inc.)6,7
Durasolv is Cima's second-generation fast-dissolving/disintegrating tablet
formulation. Produced in a fashion similar to Orasolv, Durasolv has much higher
mechanical strength than its predecessor due to the use of higher compaction
pressures during tableting. The Durasolv product is thus produced in a faster and
more cost-effective manner. Durasolv is so durable that it can be packaged in either
traditional blister packaging or vials. The newest Durasolv formulation, NuLev, is
actually dispensed in a conventional stock bottle. Pharmacists are advised to take
care when dispensing such Durasolv formulations from stock bottles to ensure they
are not exposed to high levels of moisture or humidity. Excess handling of tablets
can introduce enough moisture to initiate dissolution of the tablet matrix. One
disadvantage of Durasolv is that the technology is not compatible with larger doses
of active ingredients, because the formulation is subjected to such high pressures on
compaction. Unlike Orasolv, the structural integrity of any taste masking may be
compromised with high drug doses. The drug powder coating in Durasolv may
become fractured during compaction, exposing the bitter-tasting drug to a patient's
taste buds. Therefore, the Durasolv technology is best suited for formulations
including relatively small doses of active compound.
WOWTAB (Yamanouchi Pharma Technologies, Inc.) 16
The WOWTAB fast-dissolving/disintegrating tablet formulation has been on
the Japanese market for a number of years. It has just recently been introduced into
the U.S. The WOWTAB technology utilizes sugar and sugar-like (e.g., mannitol)
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excipients. The two different types of saccharides are combined to obtain a tablet
formulation with adequate hardness and fast dissolution rate. Due to its significant
hardness, the WOWTAB formulation is a bit more stable to the environment than
the Zydis or Orasolv. It is suitable for both conventional bottle and blister
packaging. The taste masking technology utilized in the WOWTAB is proprietary,
but claims to offer superior mouth feel due to the patented SMOOTHMELT action.
The WOWTAB product dissolves quickly in 15 seconds or less. The WOW in
WOWTAB signifies the tablet is to be given Without Water. Two WOWTAB
formulations currently on the U.S. markets are Benadryl Allergy and Sinus
FASTMELT and Children's Benadryl Allergy and Cold FASTMELT.
Other Technologies
Flash Dose (Fuisz Technologies), Flashtab (Prographarm Group), and
OraQuick (KV Pharmaceutical Co., Inc.) are three formulations on the worldwide
market. Biovail Corp. recently announced the filing of an NDA for a FlashDose
version of zolpidem tartrate. These technologies are similar to Zydis, WOWTAB,
Orasolv and Durasolv in that they dissolve or disperse on the tongue within a
minute. However, each also has unique characteristics to differentiate itself from the
competition.
FLASHDOSE (Fuisz Technologies, Ltd.) 16
Fuisz Technologies has three oral drug delivery systems that are related to
fast dissolution. The first two generations of quick-dissolving tablets, Soft Chew and
EZ Chew, require some chewing. However, these paved the way for Fuisz's most
recent development, FlashDose. The FlashDose technology utilizes a unique
spinning mechanism to produce a floss-like crystalline structure, much like cotton
candy. This crystalline sugar can then incorporate the active drug and be compressed
into a tablet. This procedure has been patented by Fuisz and is known as Shearform.
The final product has a very high surface area for dissolution. It disperses and
dissolves quickly once placed onto the tongue. Interestingly, by changing the
temperature and other conditions during production, the characteristics of the
product can be altered greatly. Instead of a floss-like material, small spheres of
saccharides can be produced to carry the drug. The process of making microspheres
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has been patented by Fuisz, and is known as CEFORM1 and serves as an alternative
method of taste masking.
FLASHTAB (Prographarm Group)16
The Flashtab technology is yet another fast-dissolving/disintegrating oral
tablet formulation. It utilizes most of the same excipients as in conventional
compressed tablets. A disintegrating agent and a swelling agent are used in
combination with coated drug particles in this formulation to produce a tablet that
disintegrates in the mouth in less than one minute.
ORAQUICK (KV Pharmaceutical Co., Inc.) 28
The OraQuick fast-dissolving/disintegrating tablet formulation utilizes a
patented taste masking technology. KV Pharmaceutical claims its microsphere
technology, known as Micro Mask, has superior mouth feel over taste-masking
alternatives. The taste masking process does not utilize solvents of any kind, and
therefore leads to faster and more efficient production. Also, lower heat of
production than alternative fast-dissolving/disintegrating technologies makes
OraQuick appropriate for heat-sensitive drugs. KV Pharmaceutical also claims that
the matrix that surrounds and protects the drug powder in microencapsulated
particles is more pliable, meaning tablets can be compressed to achieve significant
mechanical strength without disrupting taste masking. OraQuick claims quick
dissolution in a matter of seconds, with good taste masking.
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A list of Patented Technologies using manufacturing techniques and
description:4,6,7.
Technology Basis for technology Company
Zydis Lyophilization R. P. Scherer Inc.
Quicksolv Lyophilization Janseen Pharmaceutical
Lyoc Lyophilization Farmlyoc
Flashtab
Multiparticulate
Compressed Tablets
Ethypharm
Orasolv, Durasolv Compressed Tablets Cima Labs Inc.
Rapitab Compressed Tablets Schwarz Pharma
Wowtab
Compressed Molded
Tablets
Yamanouchi
PharmaTechnologies, Inc.
Fastmelt Molding Élan Corp.
Ziplets Molding Eurand
Flashdose Cotton-candy process Fuisz Technology Ltd.
SOLID DISPERSION:
Definition: 29 Solid dispersion in the pharmaceutical field are dispersion of one or
more active ingredients, generally poorly water soluble drugs, in an inert carrier or
matrix at solid state which are prepared by either melting the two (fusion) or
dissolving them in a solvent or a combination of approaches followed by removal of
the solvent.
METHODS FOR PREPARING SOLID DISPERSION:
(A) Hot melt method
Sekiguchi and Obi30 used a hot melt method to prepare simple eutectic
mixtures. In this method the drug and carrier were melted together at a temperature
above the eutectic point (melting point). The molten mixture is then cooled rapidly.
The resultant solid eutectic was then milled to reduce the particle size. Cooling leads
to supersaturation, but due to solidification the dispersed drug becomes trapped
within the carrier matrix. Whether or not a molecular dispersion can be achieved
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depends on the degree of supersaturation and rate of cooling attained in the process.
In other words, the process has an effect on the resultant dispersion and can be
varied to optimize the product.
(B) Solvent Method
Tachibani and Nakumara31 were the first to use the solvent method. This
process uses organic solvents to dissolve and intimately disperse the drug and carrier
molecule. An important prerequisite for the manufacture of a solid dispersion using
the solvent method is that both the drug and the carrier are sufficiently soluble in the
solvent. The solvent can be removed by any one of a number of methods.
Temperatures used for solvent evaporation usually lie in the range of 23-65 ºC. The
solvent can also be removed by freeze-drying or by spray-drying.
(C) Melting solvent method: 29
In the case where there is difficulty with thermal instability and immiscibility
between the drug and the carrier, the hybrid melting solvent method can be
employed.
The drug is first dissolved in a small quantity of organic solvent and added to
the molten carrier. The solvent is then evaporated to generate a product that is
subsequently milled to produce a powder.
Dosage form development:
Solid dispersion must be developed into convenient dosage forms, such as
tablets or capsules, for their clinical use and successful commercialization. Solid
dispersions produced my melt method are usually hardened at very low temperatures
and then pulverized with mortar and pestles. Similarly, solid dispersions produced
by the solvent method are also pulverized after solvent removal and hardening.
Some of the challenges in the dosage form development of such materials are
difficulty of pulverization and sifting of the dispersions, which are usually soft and
tacky, poor flow and mixing properties of powders thus prepared, poor
compressibility, drug-carrier incompatibility, and poor stability of dosage forms.3
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A COMPARISION BETWEEN CONVENTIONAL SOLID DOSAGE FORMS AND ODIS
MANUFACTURING PROCESSES USED TO PRODUCE SOLID DISPERSION
CONVENTIONAL SOLID DOSAGE
FORMS
ORALLY DISINTEGRATING
TABLETS
Swallowing problem interferes with
patient compliance
Disintegrates in oral cavity, improving
patient compliance
Reaches stomach in solid form, where it
disintegrates and is absorbed
Reaches stomach in liquid form, which
has several advantages:
1. Improved patient compliance
2. Faster onset of remedial action
3. Patient convenience
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Hypertension
Hypertension is a chronic medical condition in which the blood pressure is elevated.
It is also referred to as high blood pressure or shortened to HT, HTN or HPN. The
word "hypertension", by itself, normally refers to systemic, arterial hypertension.
Hypertension can be classified as either essential (primary) or secondary. Essential
or primary hypertension means that no medical cause can be found to explain the
raised blood pressure and represents about 90-95% of hypertension cases. Secondary
hypertension indicates that the high blood pressure is a result of (i.e., secondary to)
another condition, such as kidney disease or tumors (adrenal adenoma or
pheochromocytoma)
Causes of Hypertension
1. Essential hypertension:
Essential hypertension is the most prevalent hypertension type,
affecting 90-95% of hypertensive patients Although no direct cause has identified
itself, there are many factors such as sedentary lifestyle, stress, visceral obesity,
potassium deficiency (hypokalemia) obesity (more than 85% of cases occur in those
with a body mass index greater than 25), salt (sodium) sensitivity, alcohol intake,
and vitamin D deficiency. Risk also increases with aging, some inherited genetic
mutations and family history. An elevation of renin, an enzyme secreted by the
kidney, is another risk factor, as is sympathetic nervous system overactivity. Insulin
resistance which is a component of syndrome X, or the metabolic syndrome is also
thought to contribute to hypertension. Recent studies have implicated low birth
weight as a risk factor for adult essential hypertension.
2. Secondary hypertension
Secondary hypertension by definition results from an identifiable cause. This
type is important to recognize since it's treated differently than essential type by
treating the underlying cause. Many secondary causes can cause hypertension; some
are common and well recognized secondary causes such as Cushing's syndrome,
which is a condition where both adrenal glands can overproduce the hormone
cortisol. Hypertension results from the interplay of several pathophysiological
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mechanisms regulating plasma volume, peripheral vascular resistance and cardiac
output, all of which may be increased. More than 80% of patients with Cushing's
syndrome have hypertension.] Another important cause is the congenital abnormality
coarctation of the aorta
Mechanism of hypertension:
Most of the mechanisms associated with secondary hypertension are generally
fully understood. However, those associated with essential (primary)
hypertension are far less understood. What is known is that cardiac output is
raised early in the disease course, with total peripheral resistance (TPR) normal;
over time cardiac output drops to normal levels but TPR is increased.
Three theories have been proposed to explain this:
 Inability of the kidneys to excrete sodium, resulting in natriuretic factors
such as Atrial Natriuretic Factor being secreted to promote salt excretion
with the side effect of raising total peripheral resistance.
 An overactive Renin-angiotensin system leads to vasoconstriction and
retention of sodium and water. The increase in blood volume leads to
hypertension.
 An overactive sympathetic nervous system, leading to increased stress
responses.
It is also known that hypertension is highly heritable and polygenic (caused by
more than one gene) and a few candidate genes have been postulated in the
etiology of this condition.
Recently, work related to the association between essential hypertension and
sustained endothelial damage has gained popularity among hypertension
scientists. It remains unclear however whether endothelial changes precede the
development of hypertension or whether such changes are mainly due to long
standing elevated BP.
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Symptoms of hypertension:
Mild to moderate essential hypertension is usually asymptomatic. Accelerated
hypertension is associated with headache, somnolence, confusion, visual
disturbances, and nausea and vomiting (hypertensive encephalopathy). Some signs
and symptoms are especially important in infants and neonates such as failure to
thrive, seizure, irritability or lethargy, and respiratory distress In children,
hypertension may cause headache, fatigue, blurred vision, epistaxis, and bell palsy.
Some signs and symptoms are especially important in suggesting a secondary
medical cause of chronic hypertension, such as centripetal obesity, "buffalo hump,"
and/or wide purple abdominal striae and maybe a recent onset of diabetes suggest
glucocorticoid excess either due to Cushing's syndrome or other causes..
Mechanism of action Calcium channel blockers:
Calcium channel blockers work by blocking voltage-gated calcium channels
(VGCCs) in cardiac muscle and blood vessels. This decreases intracellular calcium
leading to a reduction in muscle contraction. In the heart, a decrease in calcium
available for each beat results in a decrease in cardiac contractility. In blood vessels,
a decrease in calcium results in less contraction of the vascular smooth muscle and
therefore an increase in arterial diameter (CCB's do not work on venous smooth
muscle), a phenomenon called vasodilation. Vasodilation decreases total peripheral
resistance, while a decrease in cardiac contractility decreases cardiac output. Since
blood pressure is determined by cardiac output and peripheral resistance, blood
pressure drops.
With a relatively low blood pressure, the after load on the heart decreases; this
decreases the amount of oxygen required by the heart. This can help ameliorate
symptoms of ischemic heart disease such as angina pectoris.
Unlike β-blockers, calcium channel blockers do not decrease the responsiveness of
the heart to input from the sympathetic nervous system. Since moment-to-moment
blood pressure regulation is carried out by the sympathetic nervous system (via the
baroreceptor reflex), calcium channel blockers allow blood pressure to be
maintained more effectively than do β-blockers.
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However, because calcium channel blockers result in a decrease in blood pressure,
the baroreceptor reflex often initiates a reflexive increase in sympathetic activity
leading to increased heart rate and contractility. A β-blocker may be combined with
a dihydropyridine calcium channel blocker to minimize these effects.
Ionic calcium is antagonized by magnesium ions in the nervous system. Because of
this, dietary supplements of magnesium oxide and other magnesium preparations
may increase or enhance the effects of calcium channel blockade.
Antihypertensive Drugs
Most antihypertensive drugs can effectively reduce mildly elevated blood pressure,
but their use is associated with many side effects. Thus the decision whether to use a
drug to control borderline or mild hypertension is made on the basis of the benefit:
risk ratio.
Antihypertensive Drugs Classification
Drugs influence arterial blood pressure at four effector sites- arterioles (resistance
vessels); veins (capacitance vessels); heart; and the kidneys—by several different
mechanisms. They can be classified according to their site or mode of action as
follows:
Diuretics
(i)Thiazides and related agents (hydrochlorothiazide, chlorthalidone etc.)
(ii) Loop diuretics (frusemide, bumetanide, ethacrynic acid)
(iii) Potassium-sparing diuretics (spironolactone, triamterene, amiloride)
II Sympatholytic Drugs
(i) Centrally acting agents (methyldopa, clonidine).
(ii) Ganglion blocking agents (trimethaphan).
(iii) Adrenergic neuron blocking agents (guanethidine, guanadrel, reserpine).
(iv) Beta-adrenoceptor blockers ( metoprolol, atenolol etc.)
(v) Alpha-adrenoceptor blockers (prazosin, terazosin, doxazosin,
phenoxybenzamine).
(vi) Alpha+beta blockers (labetalol, carvediol).
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III. Vasodilators
(i) Arterial (hydralazine, minoxidil, diazoxide)
(ii) Arterial and venous (nitroprusside)
IV. Calcium Channel Blockers
Felodipine, Verapamil, nifedipine, nicardipine, nitrendipine.
Angiotensin Converting Enzyme Inhibitors
Captopril, enalparil.
VI. Angiotensin II Receptor Blockers
Losartan, valsartan
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REVIEW OF LITERATURE
1. Vasillios et al.43 have studied the effect of hydrogen bonding in solid
dispersions of antihypertensive and antianginal drug Felodipine with the
poly vinyl pyrrolidone (POVIDONE) or polyvinyl alcohol (PVA) water
soluble polymers. Interaction energies, electron density, laplacian and
vibrational data showed a stronger hydrogen bond of Felodipine with
POVIDONE polymer in comparison to that with PVA.
2. Sreenivas et al44 formulated ondansetron mouth disintegrating tablets by
directly compression method by taking various disintegrants like
crospovidone, croscarmellose sodium, pregelatinised starch, sodium starch
glycolate and L-hydroxypropyl cellulose. They found the increasing order
of various polymers in decreasing the wetting time is the following order
crospovidone, croscarmellose sodium, pregelatinised starch, L-
hydroxypropyl cellulose and sodium starch glycolate. They showed
decreased wetting time with increased concentration of superdisintegrants.
Rapid disintegrating is observed in crospovidone, croscarmellose sodium
due to the rapid uptake of water and swelling effect respectively. They
concluded that 10% disintegrant concentration is suitable for the
preparation of ondansetron hydrochloride with croscarmellose sodium and
crospovidone are the best.
3. Karavas et al.45 have prepared pulsatile release formulations consisting of
two layered tablets appropriate for preventing ischemic heart disease. For
this reason the active core was constituted by a Felodipine/POVIDONE
10/90 w/w solid dispersion. Upon exposure of the prepared tablets to the
release medium it was found that the drug release rate is directly attributed
to the size of these nano dispersions while POVIDONE/Felodipine 90/10
w/w corresponds to an immediate release at an interval less than 30
minutes.
4. Gohel et al.18 prepared mouth dissolving tablets of nimesulide by preparing
granules containing nimesulide, camphor, crospovidone and lactose and
then camphor was sublimed from granules, alternatively, first tablets were
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prepared and then camphor was sublimed by vacuum. Sublimation of
camphor from tablets resulted in superior tablets as compared with tablets
prepared from granules that were exposed to vacuum.
5. Mahaparale et al.47 prepared solid dispersions of meloxicam by solvent
evaporation method with polyvinyl pyrrolidone (POVIDONE),  (PVA
6000) and (PVA 4000). The dissolution study was carried out for all solid
dispersions. All solid dispersions of Meloxicam showed higher solubility
and faster dissolution then pure drug alone. Meloxicam: POVIDONE (1:9)
ratio showed highest solubility and faster dissolution than any other solid
dispersion.
6. Desai et al.48 prepared orodissolving tablets of promethazine hydrochloride
using super disintegrants, sodium starch glycolate and croscarmellose
sodium by direct compression method. The formulations containing 4% of
sodium starch glycolate and 1-3% of croscarmellose sodium were found to
give the best results. Thus, the tablets apart from fulfilling all official and
other specifications, exhibited higher rate of release.
7. Babu et al.49 prepared solid dispersions of piroxicam in five super
disintegrants namely primogel, microcrystalline cellulose, crospovidone,
pregelatinized starch, croscarmellose sodium and with water soluble
carriers polyvinyl pyrrolidone and polyethylene glycol. Solid dispersions
of piroxicam in super disintegrants gave a marked enhancement in its
dissolution rate and dissolution efficiency. Solid dispersion in super
disintegrants could be used as an effective and efficient technique for
enhancing the dissolution rate of piroxicam a poorly soluble drug.
8. Patel et al50 formulated tablets of Piroxicam with POVIDONE K30 and
sodium lauryl sulphate with a view to increase its water solubility. Sodium
lauryl sulphate is used in solid dispersion with POVIDONE K30 by solvent
evaporation method. This solid dispersion is made to tablets by using
different disintegrating agents like sodium starch glycolate and
crospovidone. 32 factorial designs were applied for the study and they
found increase in dissolution with the superdisintegrant concentration.
They found no significant change after four weeks kept at 450C.
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9. Bolhuis et al51 prepared the solid dispersion by surface depositions of the
poorly soluble and hydrophobic drug on the surface of the hydrophilic and
highly swelling superdisintegrants. They found that the wet granulation of
drug with sodium starch glycolate show a large increase in the solubility of
the drug. The granules containing too high concentration of
superdisintegrant showed low drug release from the tablets. Thus viscous
layer of superdisintegrants in the granules describes effect during the
dissolution process.
10. Shu et al53 formulated rapid oral disintegration tablets by direct
compression using co-ground mixture of D-mannitol and crospovidone.
The tablets manufactured from a physical mixture of 30%(w/w) co-ground
mixture of D-mannitol and crospovidone (mixed ratio 9: 1) with
65.5%(w/w) of non-ground mannitol, 4%(w/w) of crospovidone, and
0.5%(w/w) of magnesium stearate had good properties for rapidly
disintegrating tablets in the oral cavity. They presumed that crospovidone
acted as a grinding assistant for D-mannitol in the co-grinding process,
enhancing the hardness of tablets by increasing the contact area among
powder particles.
11. Patel et al54 selected crospovidone from three superdisintegrants as the
prime study by considering wetting time and disintegrating time. In this
work rofecoxib tablets were prepared by wet granulation method. Then
they conducted study on optimizing the concentration of crospovidone and
they concluded 10 % concentration as the best concentration for preparing
fast disintegrating tablets. To these results 32 factorial design was
employed taking concentration of crospovidone and mannitol as
independent variable and wetting time and disintegration time as the
dependent variables. The best formulae were compared with two marketed
formulations and the obtained formulae showed better dissolution than
marketed products.
12. Mahajan et al55 prepared mouth dissolving tablets of sumatropan sulphate
by using disintegrants sodium starch glycolate, carboxymethyl cellulose,
Treated agar by direct compression. The tablets disintegrate by invitro and
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in vivo methods in 10 minutes. The formulation containing combination of
sodium starch glycolate and carboxymethyl cellulose was found to give the
best results when compared to carboxymethyl cellulose and agar.
13. Shimizu et al56 prepared fast-disintegrating tablet of lansoprazole. Since
lansoprazole is an antiulcer agent and is unstable under acidic conditions,
they developed lansoprazole as an orally disintegrating tablet containing
enteric-coated microgranules. The effect of compression on dissolution
behavior was investigated, as compression affected cleavage and crushing
of the enteric layer. To decrease cleavage and crushing of the enteric layer,
the effects of the combined ratio of methacrylic acid copolymer dispersion
to ethyl acrylate-methyl methacrylate copolymer dispersion and the
concentration of triethyl citrate on the dissolution in the acid stage and the
dissolution in the buffer stage were evaluated.
14. Kuchekar et al57 attempted to make mouth-dissolving tablets of salbutamol
sulphate and they employed 2n factorial design to select the
superdisintegrant from croscarmellose sodium, treated agar and sodium
starch glycolate for the formulations preparations. They employed direct
compression method for the preparations of tablets. They concluded
formulations containing sodium starch glycolate showed excellent release
compared to other formulations. They showed better release even at the
lower concentrations of sodium starch glycolate.
15. Mishra et al57 attempted to make fast disintegrating tablets of valdecoxib
usingdifferent superdisintegrants like sodium starch glycolate,
croscarmellose sodium, crospovidone and L-HPC. They used direct
compression method for the preparation of tablets. They did co-grinding of
all the ingredients prior to the tableting. The order of enhancement of
various disintegrants is in the following order L-hydroxypropyl cellulose>
Ac-Di-Sol> sodium starch glycolate > crospovidone and dissolution
obeyed Hixon Crowell cube root dissolution model.
16. Fukami et al60 formulated fast disintegrating tablets using amino acids such
as L-lysine HCl, L-alanine, glycine and L-tyrosine as disintegration
accelerator. Based on surface free energy of amino acids wetting time and
disintegration time of the tablets was examined. The wetting time of the
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tablets increased in the order of L-lysine HCl, L-alanine, glycine and L-
tyrosine, whereas the disintegration time in the oral cavity of the tablets
increased in the order of L-alanine, glycine, L-lysine HCl and L-tyrosine.
The fast disintegration of tablets was explained by the theory presented by
Matsumaru.
17. Avinash et al61 formulated highly porous mouth dissolving tablets of
domperidone by using meltable binder polyethylinglycol 4000 a diluent
mannitol and Camphor, ammonium bicarbonate that sublimes rapidly. The
later is removed from the tablets by sublimation process after compressing.
Two of the formulations having 40% w/w of ammonium bi carbonate and
20% of camphor respectively emerged to be the most satisfactory
exhibiting the disintegrating time of 19.661.53 seconds and 21.33 1.16
seconds and other parameters were found to be satisfactory.
18. Shenoy et al62 prepared fast dissolving tablets of diclofenac sodium using
direct compression by incorporating superdisintegrants like croscarmellose
sodium, sodium starch glycolate and crospovidone in different
concentrations. They found that croscarmellose sodium is best
superdisintegrant compared to others and crospovidone and sodium starch
glycolate do not show much effect may be due to secondary burst effect
and the pore size increase with increase in superdisintegrant and matrix
will have enough pressure to with stand. Another reason could be that in
the presence of disintegrant the matrix might distort and allow the
superdisintegrants to be absorbed faster.
19. Fukami et al65 prepared rapidly disintegrating tablets using glycine as a
disintegrant. They evaluated the disintegration behavior of tablets in oral
cavity. The tablets containing carboxymethyl cellulose showed the least
wetting time 3 seconds with 4 kg hardness and showed the fastest
disintegration due to excellent wetting property. They also studied the
effect of ethanzamide and ascorbic acid on disintegration time. They
observed that ethanzamide has no effect on disintegration property.
However, the disintegration time increases with ascorbic acid.
20. Chaudhari et al67 masked the bitter taste of the drug by complexing with
eudragid E100 at different concentrations of 1:1 to 1:10. Moth dissolving
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tablets were prepared by using Ac-Di-Sol and polyplastadone as
superdisintegants. They used direct compression as the method of
preparation of tablets. They found that all the formulations showed faster
release compared to marketed products that show 20 min for the 100% all
formulations showed 81% to 87% release of the drug in first 2 minutes.
Stability studies showed that there is a slight increase in disintegration time
and decreased in dissolution may be due to formation of lumps of eudragid.
21. Ahmed et al69 developed ketoprofen tablets which dissolve rapidly in the
mouth, therefore needing not to be swallowed. The solubility and
dissolution rate of poorly water soluble ketoprofen was improved by
preparing lyophilized tablets (LT) of ketoprofen using freeze drying
technique. Results obtained from dissolution tablets showed that
lyophilized tablets of ketoprofen significantly improved the dissolution rate
of the drug compared with the physical mixture and the plain drug.
22. Pawar et al70 prepared solid dispersions of trimethoprim by fusion method
using polyethylene glycol 4000, polyethylene glycol 6000 and mannitol as
carriers. Two carriers proportions were used in each case. All solid
dispersions showed increased dissolution rate as compared to pure
trimethoprim. Mannitol dispersion showed higher dissolution rate then
polyethylene glycol 4000 and polyethylene glycol 6000 dispersions.
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AIM AND OBJECTIVES
AIM
To design and develop fast dissolving tablets of felodipine using solid
dispersion and sublimation method.
OBJECTIVE
Now a day fast dissolving tablets are gaining more importance in the market.
Currently these tablets are available in the market for treating many disease
conditions. More is concerned on hypertension, migraine, dysphasia, nausea and
vomiting, Parkinson’s disease, schizophrenia . These conditions are those which
require the drug to be formulated as fast dissolving tablets. Some patient prefers fast
dissolving tablets to conventional tablets because of ease of administration,
swallowing, pleasant taste and the availability in several flavors.
Felodipine which is used in the present study is a dihydropyridine
derivative, widely accepted for its excellent antihypertensive and antianginal
properties since it is calcium antagonist compound (calcium channel blocker).
Felodipine is practically insoluble in water and its dissolution rate is limited by its
physicochemical properties36. For poorly soluble orally administered drugs the rate
of absorption is often controlled by the rate of dissolution. The rate of dissolution
can be increased by increasing the surface area of available drug by various methods
(micronization, complexation, solid dispersion etc). Another prerequisite for the fast
dissolution may be the disintegration time of tablets. Because, faster disintegration
of tablets delivers a fine suspension of drug particles and thus, greater dissolution of
the drug40.
Though, fast disintegrating tablets are prepared by many processes direct
compression using superdisintegrants is more preferred method since it is
economical and includes less procedure steps.
Effect of method of preparation (i.e. solid dispersion and sublimation) on
dissolution rate, disintegration time and wetting time was studied.
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PLAN OF WORK
 Selection of drug.
 Preformulation studies.
 FT-IR study
 Construction of standard curve
 Preparation of solid dispersion
 Characterization of solid dispersion by XRD.
 Formulation by using sublimation method.
 Selection of method for Fast dissolving tablet. (Direct compression).
 Evaluation of FDT tablet by,
 Tablet Physical Appearance
 Weight variation
 Friability
 Thickness
 Hardness
 Disintegration time
 Wetting time
 In-vitro dissolution study
 Accelerated stability study of Fast Dissolving tablet.
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DRUG PROFILE33-36
Felodipine which is used in the present study as a model drug, is a
dihydropyridine derivative, that is chemically described as ethyl methyl-4-(2,3,
dichlorphenyl) -1- 4- dihydro-2, 6- dimethyl pyridine -3,5-dicarboxylate.
Cl
N
H
O O
OO
Cl
It is white or light yellow, crystalline powder.
It is practically insoluble in water, freely soluble in dehydrated alcohol, in
acetone, in dichloro methane and in methyl alcohol.
Protein binding: 99% bound to albumin fraction.
Bioavailability: Approximately 20%.
Half life(t1/2): 8 to 18 hrs.
Mechanism of Action:
Felodipine blocks the calcium inflow into cells. It is 100 times, more active
against calcium channels in blood vessels then in the heart. It causes
peripheral vasodilation, reduction of resistance and fall of blood pressure. No
action in the heart and on the venous channels. Renal blood flow increases.
In patients with congestive failure causes reduction in pulmonary wedge
pressure with improvement in symptoms. In angina, increase in excersice
tolerance and reduction in frequency and intensity of angina attacks.
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Pharmacokinetics:
Felodipine is almost completely absorbed from the gastrointestinal tract after
oral doses but undergoes extensive first pass metabolism, with a
bioavailability of about 15%. It is extensively metabolized in the gut and the
liver and is excreted almost entirely as metabolites, about 70% of a dose
being excreted in urine and the remainder in faeces. The terminal elimination
half life is reported to be 11 to 16 hours after oral administration of an
immediate release preparation. Felodipine is about 99% bound to plasma
proteins.
Uses and administration:
Felodipine is a dihydropyridine calcium-channel blocker. It is used in the
management of hypertension and angina pectoris.
Contraindication:
Unstable angina, uncontrolled heart failure
Adverse effects:
Flushing, headache, palpitation, dizziness, fatigue, gravitational oedema,
rarely rash, pruritus, cutaneous vasculities, gum hyperplasia, urinary
frequency, impotency and fever.
Dosage:
In hypertension the usual initial dose is 5mg daily; the usual maintenance
dose is 2.5-10 mg daily and doses above 20 mg daily are not usually needed.
In angina the usual initial dose is 5mg daily increases if necessary to 10 mg
daily.
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EXCIPIENT PROFILE
MANNITOL37
Synonyms : Cordyceptic acid, manita, manna sugar, Pearlitol.
Chemical name : 1-Ethenyl-2-pyrrolidinone homopolymer.
Structural formula :
Functional category : Tablet and capsule  diluent,  sweetening  agent,
tonicity agent, vehicle (bulking agent) for lyophilized
preparations.
Applications : As a diluent in tablets (10-90% w/w). It is not
hygroscopic and can be used in moisture sensitive
active ingredients. In the manufacture of chewable
tablet formulations because of negative heat of
solution.
Description : White, Odorless, crystalline powder or free flowing
granules, it has a sweet taste.
Solubility : freely soluble in water practically insoluble in ether.
Storage conditions : Bulk materials should be stored in a well closed
container, in a cool, dry place.
Incompatibilities        : Mannitol solution, 20% w/v  or   stronger, may be
salted out by sodium or potassium chlorides. It has
incompatibility with xylitol infusion and may form
complexes with metals like Fe, Al and Cu.
Safety : When consumed orally in large amount laxative
effect may occur.
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LACTOSE37:
Synonyms : Lactose monohydrate, Lactosum monohydricum
Chemical name : O-β-D-Galactopyranosyl-(1→4)-α-D-glucopyranose
anhydrous
Structural formula :
Functional category: Diluent for dry-powder inhalers; tablet and capsule
diluent.
Description : Lactose occurs as white to off-white crystalline
Particles or powder.  Lactose is odorless and slightly
Sweet tasting; α-lactose is approximately 15% as
sweet as sucrose, while β-lactose is sweeter than the
α-form.
Solubility : Practically insoluble in chloroform,ethanol and ether;
soluble in water in 1: 4.63 at 20˚C, 1: 3.14 at 40˚C,
2.04 at 50˚C, 1:1.07 at 80˚C.
Storage conditions : Mold growth may occur under humid condition (80%
RH and above). Lactose may develop a brown
coloration on storage, the reaction being accelerated
by warm, damp condition. Saturated solution of β-
lactose may precipitate crystals of α-lactose on
standing. Solution also shows mutarotation. Lactose
should be stored in well-closed container in a cool, dry
place.
,  .   ,
Chapter 5 Drug Profile
Dept of Pharmaceutics 39 J.K.K.Nattraja College of Pharmacy
Applications in pharmaceutical formulation and technology:
Lactose is widely used as a filler or diluent in tablets and capsules, and to a
more limited extent in lyophilized products and infant feed formulae. Lactose is also
used as a diluent in dry-powder inhalation.  Various lactose grades are commercially
available that have different physical properties such as particle size distribution and
flow characteristics. This permits the selection of the most suitable material for a
particular application; for example, the particle size range selected for capsules is
often dependent upon the type of encapsulating machines used. Usually, fine grades
of lactose are used in the preparation of tablets by the wet-granulation method or
when milling during processing is carried out, since the fine permits better mixing
with other formulation ingredients and utilizes the binder more efficiently. In
lyophilized products lactose is added to freeze-dried solution to increase plug size
and aid caking. Lactose is also used in combination with sucrose (appx.1:3) to
prepare sugar-coating solutions.
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CROSPOVIDONE37
Synonym : Crosslinked povidone, polyvinylpolypyrrolidone;
1-vinyl-2-pyrrolidinone homopolymer, Kollidon CL,
Polyplasdone XL, Polyplasdone XL-10.
Chemical name : 1-Ethenyl-2-pyrrolidinone homopolymer
Chemical structure :
Functional category : Disintegrant
Description : It is a  white   to   creamy   white,   finely   divided
Free flowing, practically tasteless, odorless or nearly
odorless, hygroscopic powder.
Applications in pharmaceutical formulation:
Crospovidone is a water insoluble disintegrant. It rapidly exhibits high
capillary activity and pronounced hydration capacity with little tendency to gel
formation. Crospovidone superdisintegrant is effective in wet granulation, dry
granulation and direct compression in tablet processing. They are manufactured
using a unique process. Unlike most polymeric disintegrants, which consist of a
natural or semi-natural water-soluble polymer, which is then cross-linked
chemically, the polymerization and cross-linking occurs simultaneously to yield a
controlled insoluble mass.  This results in amorphous, spherical particles that are
then spray dried to produce a free flowing compressible powder to enable even
distribution and excellent powder flow.
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The spherical particles unique to crospovidone superdisintegrant distribute
evenly throughout the tablet and have a greater surface area/volume ratio than other
disintegrants. This feature, coupled with the amorphous open structure of the
particles, results in rapid swelling in all directions in the presence of any
physiological fluid. This leads to the rapid development of high internal stresses,
which cause the tablet to disintegrate. The fully cross-linked nature of crospovidone
means that it is completely insoluble and will not develop any viscosity. Feature
and benefits of crospovidone superdisintegrant:
Unique Chemistry:
High swell pressure
Highly effective at low concentration
Cost-effective
Completely insoluble
Will not gel during tablet dissolution ensuring
smooth processing and disintegration
performance Excellent reproducibility.
Synthetic
Consistent quality and no danger of microbial
contamination.
Not a sodium salt
Low sodium level is important for compatibility
issues and for low sodium diet.
Compatible with all drugs Give product confidence
Official in all major
pharmacopoeias
Accepted globally by licensing authorities
Unique Morphology
Rapid swelling in all directions
High performance
Cost-effective
Excellent flowability
Provides process flexibility and uniform production
possible by wet granulation or by direct
compression.
Excellent compressibility
Does not interfere with tablet compression or cause
instability on storage Improves hardness and
reduces friability
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CROSCARMELLOSE SODIUM37
Synonyms : Ac-Di-Sol, Crosslinkedcarboxymethylcellulose
sodium, modified cellulose gum, Nymcell ZSX,
Primellose, Solutab.
Chemical name : Cellulose sodium salt of carboxymethyl ether.
Structural formula :
Functional category : Tablet capsule disintegrant.
Description : Croscarmellose sodium occurs as an odorless, white
coloured powder.
Applications in pharmaceutical formulation or technology:
It swells 4-8 folds in 10 seconds. The cellulose derivative swells in two
dimensions radially. In tablet formulations, croscarmellose sodium may be used in
both direct compression and wet granulation processes. When used in wet
granulation croscarmellose sodium is added to in both the wet and dry stages of the
process so that wicking and swelling ability can both be utilized.
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MAGNESIUM STEARATE37
Synonyms : Magnesium Octadecanoate, stearic acid magnesium
Salt.
Chemical name : Octadecanoic acid magnesium salt.
Structural formula : [CH3(CH2)16COO]2Mg.
Description : It is a fine, white, precipitated or milled, impalatable
powder of low bulk density, having a faint odor of
stearic acid and a characteristic taste. The powder is
greasy to touch and adhere to skin.
Functional categories: Tablet and capsule lubricant.
Solubility : Practically in soluble in ethanol, ether, water; slightly
soluble in warm benzene and ethanol.
Stability and storage : It is stable and should be stored in well- closed
container in a cool, dry place.
Incompatibilities : Incompatible with strong acids, alkali and iron salts.
most alkaloidal salts.
Application               : It is widely used in pharmaceutical formulations. It is
used as lubricant in capsule and tablet manufacture at
concentration between 0.25- 5.0 %. It is also used in
barrier cream.
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COLLOIDAL SILICON DIOXIDE37
Synonyms : Aerosil, colloidal anhydrous silica, anhydrous silicic
acid, silicic anhydride, silicon dioxide fumed.
Structural formula : SiO2
Description : Light, loose, bluish-white coloured, odorless, tasteless,
nongritty amorphous powder.
Functional category : Adsorbent, anticacking agent, emulsion stabilizer,
glidant, Suspending agent, tablet disintegrant, thermal
stabilizer, viscosity increasing agent.
Solubility : Practically insoluble in organic solvents, water and
acids. Soluble in hot solutions of alkali hydroxide.
Stability and storage : It should be stored in a well-closed container.
Safety : It should not be administered parenterally.
Applications in pharmaceutical formulation and technology:
It is used as glidant in tabletting, to stabilize emulsions and as a thixotropic
thickening agent, suspending agent in gels and semisolid preparations, to promote
particulate suspension in aerosols. It is also used tablet disintegrant and adsorbent
dispersing agent for liquids in powders. It is frequently added to suppository
formulations containing lipophilic excipients to increase viscosity, prevent
sedimentation during molding, and decrease the release rate.
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CAMPHOR38
Synonyms : Cinnamomum Camphora
Systemic name : 1,7,7-Trimethyl bicycle [2.2.1] heptane-2-one
Molecular Formula : C10H16O
Molar Mass : 152.23 gms/mole
Description : It is a waxy, white or transparent solid with a
strong aromatic odour.
Functional Categories : Sublime agent and plasticizer.
Solubility : Solubililty in water 0.12 gms in 100 ml
Solubililty in acetic acid ~ 200gm in 100 ml
Solubililty in ethanol ~ 100 gm in 100 ml
Solubililty in acetone ~ 250 gm in 100 ml
Solubililty in ether ~ 100 gm in 100 ml
Solubililty in chloroform ~ 200 gm in 100 ml
Storage : It should be stored in well closed container and
in a cool and dry place.
Application                               : It is used as sublime agent in tablet
manufacturing. A modern use includes
plasticizers for cellulose nitrate, as an
antimicrobial agents.
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LACTOSE SPRAY DRIED
Synonyms: FlowLac 100; Lactopress Spray-Dried; NF Lactose–316 Fast Flo;
NF Lactose–315; Pharmatose DCL 11; Pharmatose DCL 14;
Super-Tab Spray-Dried.
Chemical name: Spray-dried lactose is a mixture of amorphous lactose, which
Is a 1:1 mixture of a-and-b-lactose, and O-b-
galactopyranosyl-( 1!4)-a-D- glucopyranose monohydrate.
Empirical Formula and Molecular Weight:
C12H22O11 342.30 (for amorphous)
C12H22O11_H2O 360.31 (for monohydrate)
Functional Category: Binding agent; directly compressible tablet excipient;
tablet and capsule diluent; tablet and capsule filler.
Applications in Pharmaceutical Formulation or Technology:
Spray-dried lactose is widely used as a binder, filler-binder, and flow
aid in direct compression tableting.
Description:
Lactose occurs as white to off-white crystalline particles or powder. It is
odourless and slightly sweet-tasting. Spray-dried direct-compression grades of
lactose are generally composed of 80–90% specially prepared pure a-lactose
monohydrate along with 10–20% of amorphous lactose.
Method of manufacture:
A suspension of a-lactose monohydrate crystals in a lactose solution is
atomized and dried in a spray drier(2,3) Approximately 10–20% of the total
amount of lactose is in solution and the remaining 80–90% is present in the
crystalline form. The spray-drying process predominantly produces spherical
particles. The compactibility of the material and its flow characteristics are a
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function of the primary particle size of the lactose monohydrate and the amount
of amorphous lactose.
Safety:
Lactose is widely used in pharmaceutical formulations as a diluent in
oral capsule and tablet formulations. It may also be used in intravenous
injections. Adverse reactions to lactose are largely due to lactose in tolerance,
which occurs in individuals with a deficiency of the enzyme lactase.
Handling Precautions:
Observe normal precautions appropriate to the circumstances and
quantity of material being handled. Excessive generation of dust, or inhalation
of dust, should be avoided.
Stability and Storage Conditions
Spray-dried lactose should be stored in a well-closed container in a cool,
dry place.
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TALC
Synonyms: Altalc, hydrous magnesium calcium silicate; hydrous magnesium
silicate, purified French chalk, soapstone, steatite, Magsil Star, superior.
Chemical name     : Talc
empirical formula: Mg6 (Si2O5)4(OH)4
Description:
Talc is a very fine, white to greyish-white, odourless, impalpable,
unctuous, crystalline Powder. It adheres readily to the skin and is soft to the
touch and free from grittiness.
Solubility:
Practically insoluble in dilute acids and alkalis, organic solvents, and
water.
Stability and Storage conditions:
Talc is a stable material and may be sterilized by heating at 1600C for
not less than 1 hour. It may also be sterilized by exposure to ethylene oxide or
gamma irradiation. Talc should be stored in a well-closed container in a cool,
dry place.
Functional Category   :
Anti caking agent; glidant; tablet and capsule diluents; tablet and
capsule lubricant.
Applications :
 Talc is also used as a lubricant in tablet formulations; in a novel powder
coating for extended-release pellets; and as an adsorbent.
 Talc is additionally used to clarify liquids and is also used in cosmetics
and food products, mainly for its lubricant properties.
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MATERIALS AND METHODOLOGY
INSTRUMENTATION
Sl.
no
Instruments
/Equipments
Model and Manufacturer/ supplier
1 Digital balance Shimadzu AX-200 corporation, Japan
2. Electronic balance Oriental
3 UV-Visible
spectrophotometer
UV-1700 Shimadzu corporation, Japan
4 Hot air oven Servewell instruments and equipments pvt. ltd.,
Banglore.
5 Tap density apparatus
(USP)
Electro lab, Mumbai.
6 Rotary compression
machine
Rimek mini press 1, Karnavathi engineering ltd,
Gujarat
7 Friabilator EF-2 Friabilator, Electrolab, Mumbai
8 Hardness tester Pfizer hardness tester, Servewell instruments and
equipments pvt. ltd., Banglore
9 Disintegration apparatus Electrolab ED2L Disintegration tester (USP).
10 Dissolution apparatus Electrolab TDT - 08 L Dissolution tester (USP).
11 Digital pH meter 7007, Digisun electronics, Hyderabad
12 Desiccator Tarson, Kolkata.
13 Vernier calipers RK industries, India
14 Glass ware Borosil
15 Sieves Filterwel test sieves
16 Water bath shaker Remi motors
17 FTIR Shimadzu corporation 8600, Japan
18 Stability Chamber Labcare, Mumbai
19 Vacuum Oven Labcare instrument, Bangalore.
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MATERIALS
Sl.No Material Source
1 Felodipine Gift sample, Cipla Ltd, B’lore.
2 Croscarmellose sodium Gift sample, Maple biotech pvt. Ltd, Pune.
3 Sodium starch glycolate Gift sample, Maple biotech pvt. Ltd, Pune.
4 Crospovidone Gift sample, Concertina Pharm (p) Ltd,
Hyd.
5 Microcrystalline cellulose S.D. Fine chemicals Pvt limited, Mumbai
6 Mannitol N. R. Chem. Mumbai
7 Aspartame Ranbaxy, Mumbai
8 Magnesium Stearate S.D. Fine chemicals Pvt limited, Mumbai
9 Talc S.D. Fine chemicals Pvt limited, Mumbai
10 Sodium hydroxide S.D. Fine chemicals Pvt limited, Mumbai
11 Potassium dihydrogen ortho phosphate. S.D. Fine chemicals Pvt limited, Mumbai
12 Potassium Permanganate S.D. Fine chemicals Pvt limited, Mumbai
13 Hydrochloric Acid S.D. Fine chemicals Pvt limited, Mumbai
14 Camphor Suresh chemicals,Chennai.
15 Sodium lauryl Sulphate S.D. Fine chemicals Pvt limited, Mumbai
16 Methanol S.D. Fine chemicals Pvt limited, Mumbai
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METHODS
Analytical methods for the estimation of Felodipine:
Preparation of phosphate buffer pH 6.584
Place 41.2 ml of 1M sodium dihydrogen phosphate, 39.2 ml of 0.5 M disodium
hydrogen phosphate and 1 gm of sodium lauryl sulphate were mixed and filled up
with purified water upto 1000 ml.
Determination of λ max for Felodipine:
A 5 mcg/ml solution of Felodipine in phosphate buffer pH 6.5 containing 0.1 %
sodium lauryl sulphate was scanned in UV range between 200-400 nm. Felodipine
showed maximum absorbance at 362.0 nm (fig 1) in phosphate buffer pH 6.5
containing 0.1% sodium lauryl sulphate. Thus 362.0 nm was used as wavelength
(max) for further analysis.
Preparation of calibration curve:
Weighed quantity of Felodipine (5mg) was dissolved in phosphate buffer pH 6.5
containing 0.1% sodium lauryl sulphate in 100 ml volumetric flask and the volume
was made up with the same. The stock solution obtained was 50 mcg/ml solution.
Aliquots of 0.5,1,1.5,2 and 2.5 ml if stock solution were pipetted into 25 ml standard
volumetric flasks and volume was made upto 25 ml with phosphate buffer pH 6.5
containing 0.1% sodium lauryl sulphate to give the concentration of 1, 2, 3, 4 and 5
mcg/ml. The absorbance was measured at 362.0 nm against reagent blank phosphate
buffer pH 6.5 containing 0.1% sodium lauryl sulphate (Table 1, fig 2).
Solubility studies:
The solubility of felodipine was determined in water and buffers (acid buffer pH 1.2
and phosphate buffer pH 6.5) containing different amount of solublizer. The
solubility study was conducted by taking excess amount of the drug in the 10 ml of
the solution and the solutions were kept in the water bath shaker for 48 hours. Then
the solutions were filtered and diluted with sufficient amount of the same solvent.
The absorbances of the solutions were determined at 362 nm. The solubility data for
the drug in various buffers and water is shown in table 6.
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Figure 1: UV absorption spectra of Felodipine in phosphate buffer pH 6.5
containing 0.1% sodium lauryl sulphate.
Wavelength (nm)
Table 1: Analysis of Calibartion curve data for Felodipine in phosphate buffer
pH 6.5 containing 0.1% sodium lauryl sulphate at 362.0 nm.
Sl.No Cons(µg/ml) Abs(nm)
1 0 0.00
2 1 0.021
3 2 0.043
4 3 0.060
5 4 0.082
6 5 0.102
A
b
s
o
r
b
a
n
c
e
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Figure 2: Calibration curve for Felodipine in phosphate buffer pH 6.5
containing 0.1% sodium lauryl sulphate at 362.0 nm
PREFORMULATION STUDIES45
The following preformulation studies were performed for felodipine
formulations: -
Angle of Repose:
A funnel was fixed at a particular height on a burette stand. A graph paper
was placed below the funnel on the table. The powdered drug passed through the
funnel until it forms a pile. The radius of the pile was noted down. Angle of repose
of the powder material was calculated using the formula. Results are shown in Table
5.
Angle of repose  = tan -1 H/r
Where, H is height of the pile, and r is radius of the pile.
y = 0.0208x + 0.0006
R2 = 0.9996
0
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Determination of Densities:
Apparent Bulk Density:
The bulk density, as a measure used to describe packing materials or
granules, was determined by transferring the accurately weighed amount of powder
sample to the graduated cylinder with the aid of a funnel.  The initial volume was
noted. Ratio of weight of the sample to the volume it occupied was calculated.
Tapped Density:
Weighed powder sample was transferred to a graduated cylinder and was
placed on the tapped density test apparatus, was operated for a fixed number of taps
(100).  The tapped density was determined as the ratio of weight of sample to tapped
volume.
Mass
Density =
Volume
Carr’s Index (% Compressibility):
Based on the apparent bulk density and the tapped density, the percentage
compressibility of the bulk drug was determined by using the following formula.
Tapped density –Bulk density
% Compressibility = X 100
Tapped density
Hausner’s Ratio:
The ratio of tapped density to the bulk density of the powders is called the
Hausner’s ratio. Results are shown in Table 5.
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Preparation of solid dispersions of Felodipine:
Solid dispersions of Felodipine were prepared by solvent evaporation and
melt method. Drug was weighed and taken in a china dish, dissolved in methanol
and then carrier was added (POVIDONE, PVA and Mannitol in ratio of 1:1, 1:2, 1:4
and 1:9) . The solvent was evaporated at room temperature and dried in hot air oven
at 500 C for 4 hours. The resultant mass was passed through sieve no. 60 and stored
in dessicator.
Drug content of solid dispersions:
10 mg of 1:1 solid dispersions, 15 mg of 1:2 solid dispersions, 20 mg of 1:4
solid dispersions and 50 mg of 1:9 solid dispersions were weighed and transferred to
250 ml of volumetric flask. Dissolved in phosphate buffer pH 6.5 containing 0.1%
sodium lauryl sulphate and the volume were made up with the same. An aliquot of
the filtrate was diluted and analyzed spectrophotometrically (UV-1700, Shimadzu
Corporation, Japan) at 362 nm.
Preparation of tablets containing solid dispersions of Felodipine:
The solid dispersions equivalent to 5 mg of drug were taken. Then mixed
with directly compressible diluent and superdisintegrants in a plastic container.
Magnesium stearate and aerosil were passed through sieve no. 60, mixed and
blended with initial mixture in the plastic container followed by compression of the
blend.
Preparation of tablets by direct compression method:
Tablets containing 5 mg of Felodipine were prepared by direct compression
method and the various formulae used in the study are shown in Table 2. The drug,
diluent and superdisintegrants were properly mixed together (in a plastic container).
Aerosil and magnesium stearate were passed through mesh number 60, mixed, and
blended with initial mixture in a plastic container. The tablets were prepared by
direct compression method by manual feeding using 7 mm bi concave punches on a
‘Rimek mini press 1’ a 10 station rotary compression machine.
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Preparation of tablets by sublimation technique:
The tablets containing 5 mg of Felodipine were prepared by sublimation
method and formulae used are shown in table 3. The drug, directly compressible
diluent, super disintegrants and camphor were properly mixed together (in a plastic
container). Aerosil, magnesium stearate and talc were passed through mesh no. 60,
mixed and blended with initial mixture in a plastic container. The tablets were
prepared by direct compression method by manual feeding using 7 mm bi concave
punches on a ‘Rimek mini press 1’ a 10 station rotary compression machine. After
compression the tablets were heated by vacuum drying technique at 50o C until a
constant weight was obtained to ensure the complete removal of sublimable
component. The sublimable component was removed to make the tablet porous.
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Steps involved in sublimation method
Preparation of tablets containing Camphor:
Felodipine 5 mg was taken and then it was mixed with sprayed dried lactose,
directly compressible microcrystalline cellulose, superdisintegrants and different
concentrations of camphor (3%, 5%, 10%, 20% and 40%) in a plastic container.
Magnesium stearate, aerosil and talc were passed through sieve no. 60 mixed and
blended with initial mixture in the plastic container followed by compression of the
blend.
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Table 2: Formulae used in the preparation of tablets using POVIDONES solid
dispersion
Ingredients (mg) P1 P2 P3 P4 P
Amount of solid
Dispersion equi-
valent to 5 mg
Of drug
10.16 15.24 26.31 52.63 26.31
Lactose 109.34 104.26 93.19 66.87 93.19
MCC 20 20 20 20 20
Croscarmilose
Sodium
6 6 6 6 -
Magnesium
Stearate
1.5 1.5 1.5 1.5 1.5
Talc 1.5 1.5 1.5 1.5 1.5
Aerosil 1.5 1.5 1.5 1.5 1.5
Tablet  Weight 150 150 150 150 150
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Table 3: Formulae used in the preparation of tablets using PVA solid
dispersion
Ingredients
(mg)
E1 E2 E3 E4 E
Amount of
solid
Dispersion
equi-valent to
5 mg Of drug
10.16 14.88 24.80 50.81 24.80
Lactose 109.34 104.26 94.70 68.69 94.70
MCC 20 20 20 20 20
Croscarmilose
Sodium
6 6 6 6 -
Magnesium
Stearate
1.5 1.5 1.5 1.5 1.5
Talc 1.5 1.5 1.5 1.5 1.5
Aerosil 1.5 1.5 1.5 1.5 1.5
Tablet  Weight 150 150 150 150 150
Chapter 6 Methodology
Dept of Pharmaceutics 60 J.K.K.Nattraja College of Pharmacy
Table 4: Formulae used in the preparation of tablets using Mannitol solid
dispersion
Ingredients
(mg)
M1 M2 M3 M4 M
Amount of solid
Dispersion equi-
valent to 5 mg
of drug
9.92 15.62 26 52 52
Lactose 109.58 103.88 93.5 67.5 73.5
MCC
20 20 20 20 20
Croscarmilose
Sodium
6 6 6 6 -
Magnesium
Stearate
1.5 1.5 1.5 1.5 1.5
Talc 1.5 1.5 1.5 1.5 1.5
Aerosil 1.5 1.5 1.5 1.5 1.5
Tablet Weight 150 150 150 150 150
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Table 5: Formulae used in the preparation of tablets using Sublimation method
Ingredients
(mg)
C C1 C2 C3 C4 C5
Felodipine 5 5 5 5 5 5
Spray dried
Lactose
107.5 97 94 86.5 71.5 41.5
Directly com
Pressed MCC
30 30 30 30 30 30
Camphor - 4.5 7.5 15 30 60
Crospovidone - 6 6 6 6 6
Magnesium
Stearate
1.5 1.5 1.5 1.5 1.5 1.5
Talc 3 3 3 3 3 3
Aerosil 3 3 3 3 3 3
Tablet Weight 150 150 150 150 150 150
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EVALUATION OF TABLETS
Hardness:
Pfizer hardness tester was used for the determination of the hardness of
tablets.  Tablet was placed in contact between the plungers, and the handle was
pressed, the force of the fracture was recorded. Results are shown in Table 8.
Thickness and Diameter:
The thickness and diameter of 4 tablets (2 tablets from each batch) were recorded
during the process of compression using calipers (Mitotoyo; Japan).
Friability:
Two tablets were accurately weighed and placed in the friabilator
(Electrolab. EF-2 Friabilator) and operated for 100 revolutions.  The tablets were de-
dusted and reweighed.  Percentage friability was calculated using the following
formula.
F = (1- W0 / W) × 100
Where, W0 is the weight of the tablets before the test and W is the weight of the tablet
after the test.
The tablets that loose less than 1% weight were considered to be compliant.
Results are shown in Table 8.
Disintegration test:83
Tablets were taken and introduced in each tube of disintegration apparatus, and the
tablet rack of the disintegration apparatus was positioned into a 1-liter beaker
containing 900 ml of distilled water and the time of disintegration was recorded. To
discriminate between the formulations disintegration was done at room temperature
and disk was not used for the study.
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Wetting time:19
A piece of tissue paper folded twice was placed in a small petridish (internal
diameter = 6.5cm) containing 5 ml of distilled water. A tablet was placed on the
paper, and the time for complete wetting of the tablet was measured.
Drug Content of tablets:
Tablets were weighed individually, pulverized, and diluted to 250ml with
sufficient amount of phosphate buffer pH 6.5 containing 0.1% SLS. After that an
aliquot of the filtrate was diluted and analyzed spectrophotometrically (UV-1700
Shimadzu Corporation, Japan) at 362 nm.
Dissolution studies of tablets:
The in vitro dissolution study was carried out in the USP dissolution test
apparatus (Electrolab TDT - 08 L Dissolution tester USP) type 2 (paddle). 900 ml of
the dissolution medium (phosphate buffer pH 6.5 containing 0.1% SLS) was taken
in vessel and the temperature was maintained at 37  0.5oC. The speed of the paddle
was set at 50 rpm. 5 ml of the dissolution medium was withdrawn and the same
amount of fresh medium was replenished to the dissolution medium. The sample
withdrawn was filtered and diluted with phosphate buffer pH 6.5 containing 0.1%
SLS prior to analysis in the UV spectrophotometer (UV-1700 Shimadzu
Corporation, Japan) at 362 nm.
Stability studies of the tablet formulations:
The stability study of the tablets was carried out according to ICH guidelines
at 402oC/755%RH for three months by storing the samples in stability chamber
(Lab-Care, Mumbai).
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FTIR Studies:
IR spectra for drug, excipients and formulations P3, E3 and M4 were
recorded in a Fourier transform infrared (FTIR) spectrophotometer (FTIR 1615,
Perkin Elmer, USA) with KBr pellets.
XRD Studies:
X-ray diffraction analysis of pure drug Felodipine, POVIDONE, PVA,
Mannitol and formulations P3, E3 and M4 were performed. This was done by
measuring the 2θ ranges from 10-50 on a PW 3710 X ray generator diffractometer.
The X-ray diffraction patterns were recorded automatically using rate meter with
time per step is 0.500 sec. and scanning speed of 2θ/ minute.
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RESULTS AND DISCUSSION
Solubility studies:
The solubility studies of felodipine in water / buffer solutions were carried
out to know the solubility and decide the appropriate dissolution medium. Table 6
shows the solubility data of felodipine in water/ buffer solutions. In this study
phosphate buffer pH 6.5 containing 0.1% SLS was used as dissolution media as it
can maintain perfect sink conditions.
Table 6: Solubility study data of Felodipine
Sl.No Name of the solvent/buffer Concentration
(mg/ml) (± SD),
n=3
1 Water 0.0012 ±0.002
2 Hydrochloric acid buffer pH 1.2 0.016 ±0.092
3 Hydrochloric acid buffer
pH 1.2 + 0.1%SLS
0.021 ±0.107
4 Hydrochloric acid buffer
pH 1.2 + 0.3% SLS
0.027 ±0.074
5 Hydrochloric acid buffer
pH 1.2  + 0.5% SLS
0.163 ±0.014
6 Phosphate buffer pH 6.5 0.004 ±0.040
7 Phosphate buffer pH 6.5+ 0.1% SLS 0.054 ±0.012
8 Phosphate buffer pH 6.5+ 0.3% SLS 0.222 ±0.010
9 Phosphate buffer pH 6.5+ 0.5% SLS 0.340 ±0.029
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Precompressional Parameters:
Table 7 shows the Precompressional parameters of powder blend. There was a
change in the angle of repose of formulations as the method of preparations changed
from solid dispersion to sublimation.
Table 7: Precompressional Parameters:
Formulation
(±SD), n=3
Angle of Repose
(θ) (±SD), n=3
Compressibility
(±SD), n=3
(%) Hausner’s
Ratio
P 23.65 ± 2.22 16.66 ± 4.22 1.37 ± 0.06
P1 24.21 ± 3.52 29.57 ± 0.060 1.32 ± 0.05
P2 23.70 ± 0.28 23.80 ± 1.34 1.31 ± 0.02
P3 22.49 ± 1.12 23.60 ± 2.60 1.35 ± 0.04
P4 34.06 ± 0.95 27.22 ± 1.67 1.32 ± 0.03
E 23.38 ± 0.25 23.00 ± 2.30 1.24 ± 0.02
E1 32.90 ± 1.30 20.00 ± 2.50 1.25 ± 0.07
E2 22.18 ± 1.45 27.41 ± 2.10 1.37 ± 0.02
E3 30.10 ± 1.91 23.85 ± 0.60 1.30 ± 0.00
E4 28.72 ± 0.50 18.62 ± 0.32 1.22 ± 0.09
M 24.68 ± 1.80 27.41 ± 0.75 1.37 ± 0.02
M1 22.76 ± 0.35 23.80 ± 4.60 1.31 ± 0.06
M2 24.58 ± 0.90 27.41 ± 0.60 1.37 ± 0.01
M3 23.70 ± 3.00 23.80 ± 0.50 1.28 ± 0.02
M4 25.60 ± 2.80 22.80 ± 0.64 1.30 ± 0.01
C 33.80 ± 0.51 16.66 ± 5.00 1.20 ± 0.03
C1 22.99 ± 0.72 22.61 ± 3.42 1.57 ± 0.05
C2 22.12 ± 1.52 25.80 ± 2.26 1.34 ± 0.04
C3 22.49 ± 2.20 20.00 ± 1.20 1.25 ± 0.05
C4 23.90 ± 4.20 22.80 ± 0.60 1.20 ± 0.02
C5 22.59 ± 0.89 25.45 ± 1.22 1.34 ± 0.03
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Angle of Repose ranged between 22.42 to 34.06, 22.18 to 32.90, 22.76 to 25.60,
22.12 to 33.80 in POVIDONE, PVA and mannitol solid dispersions formulations
and camphor sublimation respectively.
% compressibility ranged from 16.66 to 29.59, 18.62 to 27.41, 22.80 to 27.41 and
16.66 to 25.80 in POVIDONE, PVA and mannitol solid dispersions formulations
and Camphor sublimation respectively.
Hausners ratio increased from 1.31 to 1.37, 1.22 to 1.37, 1.28 to 1.37 and 1.20 to
1.57 in POVIDONE, PVA and mannitol solid dispersions formulations and camphor
sublimation respectively. Although, flow parameters showed varying results, most
of the formulation showed good flow property.
Postcompressional parameters:
Hardness:
Table 8 shows that, hardness of the tablet increased when mannitol was used as a
carrier, where as the  hardness of the tablets prepared by sublimation method has
been decrease .64
% Friability:
Table 8 shows the friability values of all the tablet formulations. The results
indicated that the % friability of formulations was between 0.21% and 0.64%. The
low values of friability indicate that tablets were mechanically hard enough.
Thickness:
As shown in the table 8, thickness of the tablets range from 3.28 to 3.95 mm. Tablets
prepared with mannitol showed highest thickness because of their least density.
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Table 8: Post compressional parameters of Tablets
Formulation Hardness test
(kg/cm2) (±SD), n=6
Friability (%)
(±SD), n=10
Thickness (mm)
(±SD), n=4
P 4.50 ± 0.28 0.26 ± 0.04 3.50 ± 0.00
P1 3.55 ± 0.10 0.30 ± 0.04 3.65 ± 0.050
P2 3.55 ± 0.15 0.32 ± 0.02 3.48 ± 0.058
P3 3.50 ± 0.20 0.33 ± 0.04 3.50 ± 0.060
P4 6.05 ± 0.31 0.33 ± 0.02 3.42 ± 0.055
E 3.08 ± 0.20 0.26 ± 0.02 3.75 ± 0.050
E1 4.50 ± 0.25 0.32 ± 0.05 3.80 ± 0.100
E2 5.09 ± 0.40 0.26 ± 0.06 3.84 ± 0.060
E3 4.50 ± 0.35 0.24 ± 0.00 3.82 ± 0.072
E4 3.57 ± 0.32 0.46 ± 0.01 3.68 ± 0.075
M 4.00 ± 0.45 0.42 ± 0.04 3.95 ± 0.050
M1 3.55 ± 0.10 0.30 ± 0.04 3.88 ± 0.058
M2 4.50 ± 0.15 0.50 ± 0.02 3.93 ± 0.090
M3 4.08 ± 0.40 0.33 ± 0.03 3.70 ± 0.060
M4 4.50 ± 0.35 0.26 ± 0.06 3.75 ± 0.072
C 4.50 ± 0.12 0.40 ± 0.02 3.28 ± 0.050
C1 3.09 ± 0.20 0.21 ± 0.01 3.75 ± 0.075
C2 3.00 ± 0.25 0.33 ± 0.03 3.68 ± 0.078
C3 2.50 ± 0.30 0.28 ± 0.00 3.53 ± 0.058
C4 2.08 ± 0.35 0.30 ± 0.01 3.48 ± 0.055
C5 2.00 ± 0.20 0.64 ± 0.02 3.52 ± 0.055
Note : Values in parenthesis are standard deviation (±SD)
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Figure 3: Hardness and Disintegration time of tablets prepared with
POVIDONE solid dispersion.
Figure 4: Hardness and Disintegration time of tablets prepared with PVA solid
dispersion.
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Figure 5: Hardness and Disintegration time of tablets prepared with Mannitol
solid dispersion.
Figure 6 Hardness and Disintegration time of tablets prepared with Camphor
sublimation method.
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Disintegration time:
Table 9 shows the disintegration time of the formulations. Tablets prepared
with POVIDONE ( P1,P2,P3 ) , PVA ( E1,E2,E3)  and mannitol ( M1, M2,M3,M4)
disintegrated rapidly while tablets prepared with POVIDONE (P and P4 ), with PVA
( E and E4 ) and with mannitol ( M ) did not disintegrate in specified limit of time
for fast dissolving tablet. This may be due to more hardness of the tablets as these
carriers act as strong binders at higher level within the tablets. During compression,
the carrier could plasticize, soften or melt, filling the pores within tablets and thus
making them non-disintegrating. It is also possible that the soften and melted
carriers coat the disintegrants and other ingredients used in tablets, and such a
coating along with the reduction of porosity of tablets makes disintegration difficult.
As the method of preparation of tablets changed to sublimation, the disintegration
time decreased significantly regardless of the diluent used. It is because tablets
prepared by sublimation method rapidly exhibits high pores and disintegrate the
tablet rapidly. Above results shows that tablets prepared with 4 % superdisintegrants
and 40 % camphor (sublimation method) showed least disintegration time in
comparison with the all other formulations because of their lowest hardness and the
porous structure is responsible for faster water uptake, hence it facilitates wicking
action of crospovidone in bringing about faster disintegration18.
Wetting time:
Results of wetting time studies are shown in table 9. Wetting time of
formulations P, P4, E, E4, M and C were significantly higher than other
formulations.  Wetting times of the formulations C1 to C5 were significantly lower
than all remaining formulations. It is because of highest porosity of the tablets18.
Drug content of tablets:
Drug content of tablets ranged between 95.91 to 102.00 %. Results are shown in
table 10.
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Table 9: Disintegration time and wetting times of tablet formulations
Note: Values in parenthesis are standard deviation (±SD)
Formulation Disintegration
time (sec)(±SD),
n=6
Wetting  time(sec)
(±SD), n=6
P 120 ± 6.50 80 ± 5.70
P1 48 ± 2.00 35 ± 3.75
P2 42 ± 3.44 40 ± 2.20
P3 50 ± 2.90 48 ± 2.50
P4 220 ± 5.5 145 ± 8.50
E 110 ± 1.70 81 ± 4.40
E1 52 ± 2.45 42 ± 3.27
E2 50 ± 2.00 40 ± 3.16
E3 48 ± 3.50 45 ± 3.11
E4 215 ± 4.12 142 ± 5.12
M 120 ± 2.75 75 ± 4.42
M1 62 ± 1.60 40 ± 3.30
M2 52 ± 2.22 30 ± 2.20
M3 46 ± 2.45 35 ± 2.00
M4 45 ± 2.00 30 ± 1.50
C 250 ± 9.00 250 ± 5.50
C1 40 ±7.00 25 ± 6.00
C2 30 ± 1.00 22 ± 2.20
C3 25 ± 2.00 20 ± 2.00
C4 20 ± 2.10 18 ± 1.50
C5 12 ± 2.00 08 ± 2.00
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Table10 : Dissolution parameters ( t50% and t90%) and drug content of tablets.
Note: Values in parenthesis are standard deviation (±SD)
Formulation t50% (min)
(±SD), n=4
t90% (min)
(±SD), n=4
Drug content (%)
(±SD), n=6
P 7.42 ± 0.12 28.33 ± 0.30 99.00 ± 1.97
P1 1.34 ± 0.25 10.07 ± 0.25 96.15 ± 2.20
P2 1.32 ± 0.14 8.52 ± 0.19 96.15 ± 1.50
P3 1.17 ± 0.40 6.12 ± 0.26 96.00 ± 1.55
P4 12.34 ± 0.32 15.15 ± 0.22 98.00 ± 3.00
E 9.53 ± 0.05 41.34 ± 0.25 95.10 ± 0.50
E1 4.54 ± 0.95 20.48 ± 0.35 96.50 ± 2.15
E2 1.30 ± 0.80 12.05 ± 0.19 97.00 ± 2.14
E3 1.37 ± 0.05 8.20 ± 0.15 98.55 ± 2.50
E4 1.37 ± 0.11 17.28 ± 0.10 95.91 ± 3.00
M 3.50 ± 0.22 25.00 ± 0.25 98.55 ± 2.20
M1 1.44 ± 0.04 10.19 ± 0.09 98.55 ± 0.60
M2 1.19± 0.22 8.23 ± 0.42 96.00 ±1.20
M3 1.09 ± 0.06 4.40 ± 1.02 100.96 ± 0.75
M4 1.13 ± 0.20 3.60 ±1.00 96.15 ± 1.20
C 19.14 ± 0.15 59.00 ± 0.45 102.00 ± 2.27
C1 5.02 ± 0.14 7.06 ± 0.45 97.35 ± 1.50
C2 3.05 ± 1.00 5.19 ± 0.30 98.00 ± 3.30
C3 1.46 ± 1.00 3.32 ± 0.30 98.07 ± 0.90
C4 1.40 ± 0.60 2.18 ± 0.06 99.00 ± 2.20
C5 0.36 ± 0.20 0.58 ± 0.07 98.55 ± 1.50
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In vitro release studies of tablets
The dissolution of Felodipine from tablets is shown in Figures 7 to 11.  Table
10 shows the t50% and t90% values of release profiles of tablets. These values changed
with change of carriers and method of preparation of tablets.. The dissolution of the
drug from the tablets prepared by camphor sublimation method was quicker than
those prepared by solid dispersion methods using POVIDONE, PVA and mannitol
as carriers. This may be due to their lowest hardness and the porous structure is
responsible for faster water uptake, hence it facilitates wicking action of
crospovidone in bringing about faster disintegration18.crospovidone containing
tablets rapidly exhibits high capillary activity and pronounced hydration with a little
tendency to gel formation 89 and disintegrates tablets rapidly (fig.10)
The dissolution rate of tablets prepared with solid dispersions of felodipine in
the ratio 1:1, 1:2, 1:4  ( P1,P2,P3) with POVIDONE, in the ratio 1:1, 1:2, 1:4
(E1,E2,E3) with PVA and in the ratio 1:1, 1:2, 1:4, 1:9 (M1,M2,M3,M4) with
mannitol  increased significantly (P<0.05) than P, E and M respectively. This may
be due to the use of croscarmilose sodium, which causes swelling to 4-8 folds in 10
seconds37 and due to particle size reduction and improved wettability.
In addition to micronization, conversion of drug to amorphous form during the
preparation might have also contributed to the increased dissolution rates observed
with the solid dispersions52.
However, tablets prepared with POVIDONE solid dispersions in the ratio 1:9(P4)
and with PVA solid dispersion in the ratio 1:9(E4) did not further enhance the
dissolution rate unlike solid dispersions. In practice the effect of micronization is
often disappointing, especially when the drugs are encapsulated or tabletted .
This phenomenon was attributed to the agglomeration tendency of micronized,
poorly soluble, hydrophobic drugs, which effect results in a decreased effective
surface area for dissolution51. Fig 7, 8,9 shows the dissolution profiles of tablets
prepared from solid dispersions of Felodipine with POVIDONE,PVA and
MANNITOL.The dissolution rate of tablets (P1, P2, P3, E1, E2, E3, M1, M2, M3,
M4 ) increased significantly (p<0.05) than dissolution rate of tablets P, E and M
respectively
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INVITRO DISSOLUTION
Table 11: Dissolution profile of solid dispersion with POVIDONE
Figure 7: Dissolution profiles of formulations containing POVIDONE solid
dispersions
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Time(min) P1 P2 P3 P4
0 0 0 0 0
2.5 75.25 77.86 78.59 20.17
5 78.74 81.54 84.25 22.02
7.5 81.56 83.12 87.99 32.35
10 83.46 86.57 99 43.38
12.5 86.95 98.89 - 46.48
15 98.02 - - 53.26
17.5 - - - 62.67
20 - - - 72.8
25 - - - 81.27
30 - - - 96.23
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Table 12: Dissolution profile of solid dispersion of PVA
Figure 8: Dissolution profiles of formulations containing PVA solid dispersions
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2.5 37.58 69.23 70.12 69.25
5 43.94 76.24 78.25 72.58
7.5 58.37 79.57 86.27 78.41
10 65.84 83.14 99.68 82.35
12.5 71.54 90.27 - 86.41
15 80.64 98.67 - 89.48
17.5 82.74 - - 90.26
20 85.25 - - 91.87
22.5 89.86 - - 94.74
25 97.54 - - 98.24
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Table no 13: Dissolution profile of solid dispersion of MANNITOL
Figure 9: Dissolution profiles of formulations containing Mannitol solid
Dispersions
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Table 14 : Dissolution profile of sublimation method
TIME(MIN) C1 C2 C3 C4 C5
0 0 0 0 0 0
1 36.47 39.25 40.87 47.58 91.28
2 38.14 43.84 50.99 86.24 98.54
3 40.02 50.75 80.77 97.64 -
4 46.62 60.47 97.54 - -
5 69.22 84.99 - - -
6 78.68 98.54 - - -
7 85.47 - - - -
8 97.28 - - - -
Figure10: Dissolution profiles of formulations prepared by sublimation method
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Table 15: Dissolution profile of P, E, M, C (NO SUPERDISINTEGRANT)
TIME(MIN) P E M C
0 0 0 0 0
2.5 31.28 23.04 32.54 19
5 38.32 28.32 37.96 36.1
10 55.82 48.25 50.68 38.45
15 61.23 60.78 72.36 40.01
20 72.8 63.89 79.14 41.25
25 83.74 70.58 85.01 42.01
30 89.37 74.64 97.37 43.25
35 91.47 78.69 - 44.25
40 98.87 82.47 - 45.21
45 - 85.96 - -
50 - 97.68 - -
Fig.11 Dissolution profile of P,E,M,C.(NO SUPERDISINTEGRATION
ADDED)
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Figure 12: Dissolution profiles of best formulations
Drug excipients compatibility studies:
FT-IR analysis:
The IR spectrum of the pure drug felodipine used in the present study shows
characteristic absorption bands in the following IR region (Fig 12).
IR (KBR) cm-1
3370(NH Stretching)
3069(Aromatic CH stretching)
2840, 2948(Ch stretching of CH2 and CH3 Groups)
1700, 1688 (C=O stretching)
1644 (NH Bending)
1621, 1495, 1460 (C = C ring stretching)
1099 (C O C stretching)
727, 801 (Substituted benzene ring)
564 (Cl stretching)
The polymer POVIDONE (Fig 13) used in present study shows the characteristic
absorption bands in the following IR region
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Broad peak at 3424 to 3481 may be due to the hydrogen bonded OH groups.
2895  to  2955 CH stretching.1290 CH bending.
The polymer PVA (Fig 14) used in the present study shows the characteristic
absorption bands in the following IR region.
The broad peak at 3447(OH Hydrogen bonded), the peaks at 2694, 2740,
2884, 2948(CH stretching), 1342(CH bending) and 963(C-O).
The polymer Mannitol (Fig 15) used in the present study shows the
characteristic absorption bands in the following IR region.
The broad peaks at 3220 to 3405(OH hydrogen bonded), the peaks at 2719,
2902, 2948 and 2970(CH stretching), the peak at 1281(CH bending) and peak at
929(C-O).
The IR spectrum of the formulation P3 (Fig 16) shows the characteristic
absorption bands in the following IR region.
It is quite interesting to note that, the spectrum contains very broad peaks in
the range 3200 to 3500 and a very sharp peak almost merged with the broad peak at
3370 indicating the presence of OH of POVIDONE and NH of Felodipine. Further it
has the aromatic CH peak from 3050 and CH stretching of POVIDONE in the range
2836 to 2978.The spectrum shows the presence of carbonyl group of drug at 1700
and 1688,NH bending 1643 and C=C ring stretching at 1617,1496 and 1443. Since
all the major peaks of the pure drug and POVIDONE are present without any change
in their positions in the spectrum of the formulation P3 .It may be concluded that the
drug and polymer have retained their identity without loosing their properties and
not going in to a chemical interaction with each other. Thus the conclusion from the
IR spectra of the drug and formulation is that there is no interaction between drug
and polymer.
Similarly the IR spectra of formulations E3 (Fig 17) and M4 (Fig 18) reveal
that the pure drug Felodipine has not gone into the interaction with PVA in the
formulation E3 and Mannitol in the formulation M4
Chapter 7 Result and Discussion
Dept of Pharmaceutics 82 J.K.K.Nattraja College of Pharmacy
Figure 12: FTIR spectrum of felodipine
Figure 13: FTIR spectrum of POVIDONE
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Figure 14: FTIR spectrum of PVA
Figure 15: FTIR spectrum of Mannitol
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Figure 16: FTIR spectrum of formulation P3
Figure 17: FTIR spectrum of formulation E3
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Figure 18: FTIR spectrum of formulation M4
X-Ray Diffraction pattern:
One of the common approaches to improve the bioavailability of poorly
water soluble drugs is to enhance their dissolution rate by formation of amorphous
dispersions and, preferably molecular dispersions45.
X-ray diffraction patterns of formulation P3, E3 and M4 revealed that
felodipine a crystalline material shows characteristic peaks at 2θ 10.20, 10.35, 10.77,
13.16, 14.64, 16.20, 17.71, 20.48, 23.34, 24.49, 25.40, 26.47, 27.55, 29.25, 31.99,
33.89, 36.87, 39.55, 43.11, 44.64 and 47.61.However the XRD patterns of its solid
dispersion in POVIDONE, PVA and mannitol shows the typical profiles of
amorphous material as observed from the values. A peak corresponding to
felodipine crystals completely disappeared in solid dispersions prepared with
POVIDONE, PVA and mannitol.. These results indicate that drug was dispersed in
amorphous form in the solid dispersions of POVIDONE, PVA and mannitol (Fig
19-25)
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Figure 19: XRD patterns of pure Felodipine
Figure 20: XRD patterns of pure POVIDONE
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Figure 21: XRD patterns of Felodipine solid dispersion with POVIDONE
Figure 22: XRD patterns of pure PVA
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Figure 23: XRD patterns of Felodipine solid dispersion with PVA
Figure 24: XRD patterns of pure Mannitol
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Figure 25: XRD patterns of Felodipine solid dispersion with Mannitol
Stability studies:
Table 11 shoes the parameters of tablets after stability studies. The increase
(P<0.05) in the disintegration time was observed in case of tablets prepared with
mannitol solid dispersion. This may be due to increase in the hardness of the tablets
during storage87. Decrease (P<0.05) in the disintegration time was observed in
tablets prepared by camphor sublimation method. Since during the preparation of
tablets by camphor sublimation method, only 6 hours at 60oC was used, where as 90
days and 45oC were used during stability studies. The long storage of 90 days at 45 o
C might have removed trace amount camphor that was not removed during the short
period of preparation. No change was observed in the disintegration time of tablets
prepared with POVIDONE and PVA solid dispersions. No significant change in the
thickness was observed in all the tablets and drug content of all formulation was
within the acceptable limits.
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Table 16: Tablet parameters after stability studies.
Formulation Disintegration
Time (sec)
(±SD), n=6
Thickness (mm)
(±SD), n=4
% drug content
(±SD), n=6
P 140 ±10.15 3.50 ± 0.052 99.00 ± 0.62
P1 50.00 ± 6.33 3.62 ± 0.050 96.00 ± 0.72
P2 44.00 ± 4.11 3.45 ± 0.051 95.36 ± 1.35
P3 48.00 ±3.92 3.48 ± 0.062 94.72 ± 0.72
P4 240.0 ± 4.56 3.38 ± 0.039 97.62 ±1.55
E 130 ± 3.78 3.68 ± 0.084 94.65 ± 0.58
E1 55.00 ± 2.35 3.78 ± 0.081 95.75 ± 0.42
E2 52.00 ± 4.15 3.80 ± 0.045 97.00 ± 0.62
E3 50.00 ± 5.95 3.78 ± 0.080 97.31 ± 0.75
E4 230.0 ± 4.72 3.65 ± 0.072 94.91 ± 1.31
M 141.0 ± 3.15 3.88 ± 0.059 97.92 ± 2.27
M1 108.0 ± 4.90 3.68 ± 0.048 97.52 ± 2.21
M2 95.00 ± 2.72 3.72 ± 0.052 95.57 ± 2.00
M3 85.00 ± 3.57 3.68 ± 0.055 99.65 ± 1.55
M4 75.00 ± 3.50 3.72 ± 0.065 95.15 ± 1.32
C 270.0 ± 8.00 3.18 ± 0.062 100.0 ± 0.05
C1 41.00 ± 3.45 3.68 ± 0.059 97.00 ± 0.48
C2 28.00 ± 3.11 3.58 ± 0.050 98.00 ± 0.58
C3 24.00 ± 2.92 3.55 ± 0.058 97.57 ± 0.48
C4 18.00 ± 2.56 3.42 ± 0.058 98.92 ±1.31
C5 14.00 ± 3.61 3.48 ± 0.050 98.00 ± 0.90
Note: Values in parenthesis are standard deviation (±SD)
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SUMMARY
The demand for fast dissolving tablets has enormously increased during the
last decade, particularly for geriatric and pediatric patients who have difficulty in
swallowing conventional tablets and capsules. Oral administration of the drugs is
difficult in patients having concomitant vomiting or diarrhea. Fast dissolving or fast
disintegrating dosage form is advantageous for such patients. Fast dissolvable or fast
disintegrating dosage forms are meant to disintegrate immediately upon contact with
the saliva leading to faster release of the drugs in the oral cavity.
Felodipine is a dihydropyridine calcium channel blocker. It’s widely used in
the management of hypertension and angina pectoris. Felodipine is practically
insoluble in water. Here felodipine is used as a model drug in formulating the fast
dissolving tablets.
In the present work direct compression was employed to prepare tablets.
Lactose and micro crystalline cellulose were selected as diluent. Croscarmilose
sodium and crospovidone were selected as superdisintegrants. Magnesium stearate
and aerosil were selected as lubricant and glident respectively. Tablets were
compressed individually using biconcave 7mm punches in Rimek minipress 1, a 10
station rotary compression machine. Tablets were evaluated for change in
parameters by change in the method of preparation (i.e. solid dispersion with
different carriers and sublimation method)
Precompressional parameters, angle of repose, percentage compressibility
and Hausner’s ratio studies indicated that most of the formulation showed fair and
good flow properties.
Postcompressional parameters, hardness, friability, disintegration time,
wetting time, drug content, dissolution studies and stability parameters were studied.
Tablets kept for stability study at (40 ± 20 C/75± 5% RH) for 3 months. Tablets
prepared by solid dispersion with Mannitol showed slightly higher hardness than
other tablets prepared by solid dispersion with Povidone and Pva, while that of
tablets prepared by Camphor sublimation method showed least. Friability of tablets
ranged between 0.21-0.64%. Drug content of tablets ranged between 95.91-
102.00%.
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Tablets containing solid dispersion with Povidone of ratio 1:4 (P3), with Pva
of ratio 1:4 (E3) and with Mannitol of ratio 1:9 (M4) yielded best results in terms of
dissolution rate. Tablets prepared by sublimation method containing 40% Camphor
(C5) yielded best result in terms of dissolution rate.
XRD analysis revealed that there was a formation of amorphous form in all
solid dispersions. FT-IR studies revealed that, there was no incompatibility of the
drug with the excipients used.
Disintegration time of tablets prepared by solid dispersion using
mannitol, increased significantly (p<0.05) and that of those tablets prepared by
sublimation method decreased significantly (p<0.05) after stability studies.
CONCLUSION
From this study, it can be concluded that dissolution rate of felodipine could
be enhanced by tablets containing solid dispersion and sublimation technique.
Tablets prepared by sublimation method showed least disintegration times as
compared with other tablets prepared by solid dispersion method. Tablets prepared
by sublimation method showed best dissolution rate than the other tablets prepared
by solid dispersion method.
Here we have succeeded in formulating fast dissolving formulation for
Felodipine which are cost effective and have patient compliance.
Success of the present study recommends a detailed investigation in to in-
vivo studies for its effective use in clinical practice.
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